<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        31-187-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FEIBA 50U POWDER&SOLVENT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANTI INHIBITOR COAGULANT COMPLEX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8226.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAXTER AG - AUSTRIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FEIBA is a preparation made from human plasma which allows hemostasis, even when individual coagulation factors are reduced or absent.</p><p>FEIBA is used for the treatment of bleedings in inhibitor hemophilia A patients.<br />FEIBA is used for the treatment of bleedings in inhibitor haemophilia B patients, if no other specific treatment is available.<br />FEIBA is also used for prophylaxis of bleeding in inhibitor hemophilia A patients who have experienced a significant bleed or are at high risk of significant bleeding.<br />Furthermore, FEIBA may be used for the treatment of bleedings in non-hemophilic patients who have acquired inhibitors to factor VIII.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Please inform your doctor if you have a known allergy. Please inform your doctor if you are on a low-sodium diet.</p><p>Do not use FEIBA<br />In the following situations FEIBA should only be used if - for example due to a very high inhibitor titre - no response to treatment with the appropriate coagulation factor concentrate can be expected.<br />&bull;&nbsp;&nbsp; &nbsp;if you are allergic (hypersensitive) to any of the components of FEIBA.<br />&bull;&nbsp;&nbsp; &nbsp;if a disseminated intravascular coagulation (DIC) exists. (DIC = consumption coagulopathy, a life-threatening condition in which excessive blood coagulation with pronounced blood clot formation in the blood vessels occurs. This then leads to a consumption of the coagulation factors in the entire body)<br />&bull;&nbsp;&nbsp; &nbsp;in case of myocardial infarction, acute thrombosis and/or embolism: FEIBA should only be used in life threatening bleeding episodes.</p><p>Warnings and precautions<br />Talk to your doctor before before using FEIBA, because hypersensitivity reactions may occur, as is the case with all intravenously administered plasma products. To be able to recognize an allergic reaction as soon as possible, you should be aware of potential early symptoms of a hypersensitivity reaction such as<br />-&nbsp;&nbsp; &nbsp;erythema (reddening of the skin)<br />-&nbsp;&nbsp; &nbsp;skin rash<br />-&nbsp;&nbsp; &nbsp;occurrence of hives on the skin (nettle rash/urticaria)<br />-&nbsp;&nbsp; &nbsp;itching over the entire body<br />-&nbsp;&nbsp; &nbsp;swelling of lips and tongue<br />-&nbsp;&nbsp; &nbsp;breathing difficulties/dyspnoea<br />-&nbsp;&nbsp; &nbsp;tightness of the chest<br />-&nbsp;&nbsp; &nbsp;general indisposition<br />-&nbsp;&nbsp; &nbsp;dizziness<br />-&nbsp;&nbsp; &nbsp;drop of blood pressure<br />Other symptoms of hypersensitivity reactions to plasma-derived products include lethargy and restlessness. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If you notice one or more of these symptoms, stop the infusion immediately and contact your doctor straight away. The above mentioned symptoms may be early indications of an anaphylactic shock. Severe symptoms require prompt emergency treatment.</p><p>Your doctor will only re-use FEIBA in patients with suspected hypersensitivity to the product or any of its components after careful weighing of the expected benefit and the risk of re-exposure and/or no reaction with another preventative therapy or alternative therapeutic agents is to be expected.</p><p>&ndash;&nbsp;&nbsp; &nbsp;if you experience major changes in blood pressure or pulse rate, breathing difficulties, coughing or chest pain, stop the infusion immediately and contact your doctor. Your doctor will initiate the appropriate diagnostic and therapeutic measures.<br />&ndash;&nbsp;&nbsp; &nbsp;in patients with inhibitor hemophilia or acquired inhibitors to coagulation factors. Under treatment with FEIBA, these patients may have an increased bleeding tendency and an increased risk of thrombosis at the same time.</p><p>Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, have occurred in the course of treatment with FEIBA Concomitant use of recombinant Factor VIIa likely increases the risk of developing a thromboembolic event. Some of the thromboembolic events have occurred in case of treatment with high doses of FEIBA.<br />In a study performed by another company to evaluate emicizumab (a medicine to prevent bleeding in patients with hemophilia A), some patients who suffered from breakthrough bleeds were treated with FEIBA to control the bleeds, and a few of these patients developed thrombotic microangiopathy (TMA). TMA is a serious and potentially life-threatening condition. When people have this condition, the lining of the blood vessels can be damaged and blood clots may develop in small blood vessels. In some cases, this can cause damage to the kidneys and other organs. In case of breakthrough bleeds while on emicizumab prophylaxis, contact your hemophilia treater or Hemophilia Treatment Center immediately.<br />When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, and the testing of each donation and pools of plasma for signs of virus/ infections. Manufacturers of these products also include steps in the processing of the blood and plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to unknown or emerging viruses or other types of infections.<br />The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals whose immune system is depressed or who have some types of anaemia (e.g. sickle cell disease or haemolytic anaemia). &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly or repeatedly receive human plasma-derived Factor VIII inhibitor products.<br />After administration of high doses of FEIBA, the transitory rise of passively transferred Hepatitis B surface antibodies may result in misleading interpretation of positive results in serological testing.<br />FEIBA is a plasma derived product and could contain substances that react when infused in patients, causing the presence of isohemagglutinins (antibodies that cause the adhesion of red blood cells from another person). This process can lead to misleading results in blood tests.<br />It is strongly recommended that every time you receive a dose of FEIBA the name and batch number of the product are recorded in order to maintain a record of the batches used.</p><p>Other medicines and FEIBA<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>No adequate and well-controlled studies of the combined or sequential use of FEIBA and recombinant Factor VIIa, antifibrinolytics or emicizumab have been conducted. The possibility of thrombotic events should be considered when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used during treatment with FEIBA. Therefore, antifibrinolytics should not be used for approximately 6 to 12 hours after the administration of FEIBA.<br />In cases of concomitant rFVIIa use a potential drug interaction cannot be excluded according to available in vitro data and clinical observations, potentially resulting in a thromboembolic event. Tell your doctor if you are to be treated with FEIBA after you have received emicizumab (a medicine to prevent bleeding in patients with hemophilia A) as there are specific warnings and precautions to be considered. Your doctor will need to monitor you closely.<br />As in all blood coagulation preparations, FEIBA should not be mixed with other medicinal products before administration, as the efficacy and tolerance of the preparation may be impaired. It is advisable to rinse a common venous access with a physiological saline solution before and after the administration of FEIBA.</p><p>Pregnancy, breast-feeding and fertility<br />Your doctor will decide if FEIBA may be used during pregnancy and breast-feeding. Due to the increased risk of thrombosis during pregnancy, FEIBA should be administered only under careful medical monitoring and only if absolutely necessary. Information about parvovirus B19 infection is given in section warnings and precautions.</p><p>Driving and using machines<br />There are no signs that FEIBA may affect the ability to drive or to use machines. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Important information about some of the ingredients of FEIBA<br />FEIBA 50 U/ml contains approximately 4 mg sodium (calculated) per ml, it is approx. 40 mg sodium for the presentation 500 U FEIBA, approx. 80 mg sodium for the presentation 1000 U FEIBA and approx. 200 mg sodium for the presentation 2500 U FEIBA. This is to be taken into consideration for patients on low sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Reconstitute the freeze-dried FEIBA powder with the enclosed solvent and administer the solution intravenously.</p><p>Always use FEIBA exactly as your doctor has told you. You should check with your doctor or pharmacist, if you are not sure.</p><p>Taking into consideration the severity of your blood coagulation disorder, the location and extent of the hemorrhage, and your general condition and response to the preparation, your doctor has determined the dose and dosage intervals required for you personally. Do not change the dosage established by your doctor and do not discontinue the application of the preparation independently.<br />Please talk to your doctor or pharmacist if you have the impression that the effect of FEIBA is too strong or too weak.<br />Warm the product to room or body temperature prior to administration if necessary.<br />FEIBA is to be reconstituted immediately prior to administration. The solution should be used immediately (as the preparation does not contain preservatives).<br />Swirl gently until all material is dissolved. Ensure that FEIBA is completely dissolved; otherwise, less FEIBA Units will pass through the device filter.<br />Solutions, which are cloudy or have deposits, are to be disposed of appropriately. Do not reuse opened containers.<br />Use only the enclosed Water for Injections and the enclosed device set for reconstitution.<br />If devices other than those enclosed are used, ensure use of a suitable filter with at least 149 &micro;m pore size. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Do not use the product if its sterile barrier has been breached, its package damaged or if it shows signs of deterioration.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Reconstitution of the powder for preparing a solution for infusion with the BAXJECT II Hi-Flow:<br />1.&nbsp;&nbsp; &nbsp;Warm the unopened solvent vial (Water for Injections) to room temperature or max + 37&deg;C if necessary, for example by using a water bath for several minutes.<br />2.&nbsp;&nbsp; &nbsp;Remove the protective caps from the powder vial and solvent vial and disinfect the rubber stoppers of both vials. Place the vials on an even surface.<br />3.&nbsp;&nbsp; &nbsp;Open the packaging of the BAXJECT II Hi-Flow by pulling off the protective foil without touching the contents of the package (Fig. a). Do not remove the transfer system from the package at this point.<br />4.&nbsp;&nbsp; &nbsp;Turn the package around and press the transparent plastic pin through the rubber stopper of the solvent vial (Fig. b). Now remove the packaging from the BAXJECT II Hi-Flow (Fig. c). Do not remove the blue protective cap from the BAXJECT II Hi- Flow at this point.<br />5.&nbsp;&nbsp; &nbsp;Now turn the system, consisting of the BAXJECT II Hi-Flow and the solvent vial, in such a way that the solvent vial is on top. Press the purple pin of the BAXJECT II Hi- Flow through the FEIBA vial. The solvent is drawn into the FEIBA vial by vacuum (Fig. d).<br />6.&nbsp;&nbsp; &nbsp;Swirl, but do not shake the entire system gently until the powder is dissolved. Make sure that the FEIBA has been dissolved completely, as active material may otherwise be retained by the filter in the system. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Infusion<br />Use aseptic techniques throughout the entire procedure !<br />1)&nbsp;&nbsp; &nbsp;Remove the blue protective cap from the BAXJECT II Hi-Flow. Tightly connect the syringe to the BAXJECT II Hi-Flow. DO NOT DRAW AIR INTO THE SYRINGE. (Fig. e). In order to ensure tight connection between syringe and BAXJECT II Hi-Flow, the use of a luer lock syringe is highly recommended (turn syringe in clockwise direction until stop position when mounting).<br />2)&nbsp;&nbsp; &nbsp;Invert the system so that the dissolved product is on top. Draw the dissolved product into the syringe by pulling the plunger back SLOWLY and ensure that the tight connection between BAXJECT II Hi-Flow and the syringe is maintained throughout the whole pulling process (Fig. f).<br />3)&nbsp;&nbsp; &nbsp;Disconnect the syringe.<br />4)&nbsp;&nbsp; &nbsp;If foaming of the product in the syringe occurs, wait until the foam is collapsed. Slowly administer the solution intravenously with the enclosed infusion set (or disposable needle). &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Do not exceed an infusion rate of 2 U FEIBA/kg body weight per minute. If you use more FEIBA than you should:<br />Please inform your doctor immediately. Overdosage of FEIBA may increase the risk of undesired events, such as thromboembolism (formation of a blood clot with flushing into the blood vessels), consumption coagulopathy (DIC) or myocardial infarction. Some of the reported thromboembolic events occurred with doses above 200 U/kg or with patients with other risk factors for thromboembolic events. If signs or symptoms of thrombotic and thromboembolic events are observed, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, FEIBA can cause side effects although not everybody gets them.<br />Common side effects (may affect up to 1 in 10 people)<br />Hypersensitivity, Headache, Dizziness, Hypotension, Rash, Hepatitis B surface antibody positive.</p><p>Side effects with unknown frequency (the frequency cannot be estimated on the basis of the available data)<br />Blood and lymphatic system disorders: Consumption coagulopathy (DIC), Increase of inhibitor titer<br />Immune system disorders: Anaphylactic reactions, Nettle-rash on the entire body (Urticaria)<br />Nervous system disorders: Feeling of numbness in the limbs (hypoesthesia), Abnormal or reduced sensation (Paresthesia), Stroke (Thrombotic stroke, Embolic stroke), Sleepiness (Somnolence), Altered sense of taste (Dysgeusia)<br />Cardiac disorders: Heart attack (Myocardial infarction), Palpitation of the heart (Tachycardia)<br />Vascular disorders: Blood clot formation with flushing into the vessels (thromboembolic events, venous and arterial thrombosis), Increase of blood pressure (Hypertension), Flushing<br />Respiratory, Thoracic, and Mediastinal disorders: Obstruction of the pulmonary artery (Pulmonary embolism), Constriction of the air passages (Bronchospasm), Wheezing, Cough, Breathlessness (Dyspnea)<br />Gastrointestinal disorders: Vomiting, Diarrhea, Abdominal discomfort, Feeling of sickness (Nausea)<br />Skin and subcutaneous tissue disorders: Feeling of numbness in the face, Swelling of face, tongue and lips (Angioedema), Nettle-rash on the entire body (Urticaria), Itching (Pruritus)<br />General disorders and complaints at the injection site: Pain at injection site, general feeling of being unwell, feeling hot, chills, fever, chest pain, chest discomfort<br />Investigations: Drop in blood pressure, Rapid intravenous infusion can cause stabbing pain and a sensation of numbness in face and limbs, as well as a decrease in blood pressure.<br />Myocardial infarctions were observed after the administration of doses above the maximum daily dose and/or prolonged application and/or the presence of risk factors for thromboembolism. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Reporting of side effects<br />If you get any side effect, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can report side effects directly via the national reporting system as below:</p><p>To report any side effect(s):<br />Kingdom of Saudi Arabia</p><p>-National Pharmacovigilance centre (NPC)</p><p>&bull;&nbsp;&nbsp; &nbsp;Fax: +966-11-205-7662<br />&bull;&nbsp;&nbsp; &nbsp;Call NPC at +966-11-2038222, Ext: 2317-2356-2340<br />&bull;&nbsp;&nbsp; &nbsp;Reporting hotline: 19999<br />&bull;&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa<br />&bull;&nbsp;&nbsp; &nbsp;Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />- Please contact the relevant competent authority.</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children. Do not store above 25&deg;C. Do not freeze.<br />Store in the original package in order to protect from light.<br />Do not use FEIBA after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Powder<br />&ndash;&nbsp;&nbsp; &nbsp;The active substance per vial is factor VIII inhibitor bypassing activity.<br />&ndash;&nbsp;&nbsp; &nbsp;1 ml contains 50 U factor VIII inhibitor bypassing activity.<br />&ndash;&nbsp;&nbsp; &nbsp;FEIBA 50 U/ml is available in three different presentations:<br />&ndash;&nbsp;&nbsp; &nbsp;The presentation 500 U FEIBA contains 500 U (Units) factor VIII inhibitor bypassing activity in 200 &ndash; 600 mg human plasma protein<br />&ndash;&nbsp;&nbsp; &nbsp;The presentation 1000 U FEIBA contains 1000 U (Units) factor VIII inhibitor bypassing activity in 400 &ndash; 1,200 mg human plasma protein<br />&ndash;&nbsp;&nbsp; &nbsp;The presentation 2500 U FEIBA contains 2500 U (Units) factor VIII inhibitor bypassing activity in 1,000 &ndash; 3,000 mg human plasma protein.<br />FEIBA also contains factors II, IX and X, mainly in non-activated form as well as activated factor VII. Factor VIII coagulation antigen (F VIII C:Ag) as well as the factors of the kallikrein-kinin system are present only in trace amounts, if at all.<br />&ndash;&nbsp;&nbsp; &nbsp;The other ingredients are sodium chloride and sodium citrate.<br />Solvent<br />&ndash;Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The product is presented as freeze-dried powder or friable solid of white to off-white or pale green color. The pH-value of the ready to use solution is between 6.8 and 7.6.
Powder and solvent are supplied in vials made of glass and are closed with rubber stoppers.

Presentation: 1 x 500 U
1 x 1000 U
1 x 2500 U

Not all presentations may be marketed.                                                                                                                                                                                                                                                                                       Content of package:
- 1 vial with 500 U / 1000 U / 2500 U FEIBA powder for solution for infusion
-	1 vial with 10 ml / 20 ml / 50 ml Water for Injections
-	1 BAXJECT II Hi-Flow for reconstitution
-	1 disposable syringe
-	1 disposable needle
-	1 butterfly needle with clamp
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorisation holder: Baxter AG, Industriestrasse 67, A-1221 Vienna</p><p>Manufacturer:<br />Baxter AG, Industriestrasse 67 A-1221 Vienna Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in September 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>FEIBA ھو ﺗرﻛﯾﺑﺔ ﻣ ُﻌدة ﻣن اﻟﺑﻼزﻣﺎ اﻟﺑﺷرﯾﺔ ﺗﺗﯾﺢ اﻹرﻗﺎء، ﺣﺗﻰ ﻓﻲ ﺣﺎﻟﺔ ﻧﻘص ﻋواﻣل اﻟﺗﺟﻠط ﻟدى اﻟﻣرﯾض أو ﻋدم &nbsp;وﺟودھﺎ. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﯾﺳﺗﺧدم ﻓﺎﯾﺑﺎ )FEIBA( ﻟﻌﻼج اﻟﻧزﯾف ﻟدى ﻣرﺿﻰ اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ أ ذوي اﻟﻣﺛﺑطﺎت.&nbsp;<br />ﯾﺳُ ﺗﺧدم ﻓﺎﯾﺑﺎ )FEIBA( ﻟﻌﻼج اﻟﻧزﯾف ﻟدى ﻣرﺿﻰ اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ ب ذوي اﻟﻣﺛﺑطﺎت، إن ﻟم ﯾﻛن ھﻧﺎك ﻋﻼج آﺧر ﻣﺣدد ﻣﺗﺎح. &nbsp; &nbsp;ﯾﺳُ ﺗﺧدم ﻓﺎﯾﺑﺎ )FEIBA( ﻛذﻟك ﻓﻲ اﻟوﻗﺎﯾﺔ ﻣن اﻟﻧزﯾف ﻟدى ﻣرﺿﻰ اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ أ ذوي اﻟﻣﺛﺑطﺎت ﻣﻣن ﻣروا ﺑﻧزﯾف ﺷدﯾد أو ﻣن ھم أﻛﺛر ﻋرﺿﺔ ﻟﻠﻧزﯾف اﻟﺷدﯾد&nbsp;<br />وﻛذﻟك، ﯾﻣﻛن اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( ﻟﻌﻼج اﻟﻧزﯾف ﻟدى اﻟﻣرﺿﻰ ﻏﯾر اﻟﻣﺻﺎﺑﯾن ﺑﺎﻟﮭﯾﻣوﻓﯾﻠﯾﺎ ﻣﻣن اﻛﺗﺳﺑوا ﻣﺛﺑطﺎت ﻟﻠﻌﺎﻣل اﻟﺛﺎﻣن.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﯾرﺟﻰ إﺧطﺎر طﺑﯾﺑك إن ﻛﻧت ﻣﺻﺎﺑًﺎ ﺑﺣﺳﺎﺳﯾﺔ ﻣﻌروﻓﺔ. &nbsp;<br />ﯾرﺟﻰ إﺧطﺎر طﺑﯾﺑك إن ﻛﻧت ﺗﺧﺿﻊ ﻟﻧظﺎم ﻏذاﺋﻲ ﻗﻠﯾل اﻟﺻودﯾوم. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﻣواﻧﻊ اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( &nbsp; &nbsp; &nbsp; &nbsp;ﻻ ﯾﻧﺑﻐﻲ اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( ﻓﻲ اﻟﺣﺎﻻت اﻟﺗﺎﻟﯾﺔ إﻻ ﻓﻲ ﺣﺎﻟﺔ إﻣﻛﺎﻧﯾﺔ ﺗوﻗﻊ ﻋدم اﻻﺳﺗﺟﺎﺑﺔ ﻟﻠﻌﻼج ﺑﻌﺎﻣل اﻟﺗﺟﻠط اﻟﻣرﻛز اﻟﻣﻼﺋم، ﻣﺛﻠﻣﺎ ﯾﺣدث ﻋﻧدﻣﺎ ﯾﻛون ذﻟك ﺑﺳﺑب اﻻرﺗﻔﺎع اﻟﺷدﯾد ﻟﻌﯾﺎر اﻟﻣﺛﺑط. &nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣﺳﺎﺳﯾﺔ )ﻓرط اﻟﺣﺳﺎﺳﯾﺔ( ﺗﺟﺎه أي ﻣٍ ن ﻣﻛوﻧﺎت ﻓﺎﯾﺑﺎ )FEIBA(.&nbsp;<br />إن ﻛﺎن ﯾوﺟد ﺗﺟﻠط ﻣﻧﺗﺷر داﺧل اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ )DIC(. )اﻟﺗﺟﻠط اﻟﻣﻧﺗﺷر داﺧل اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ = اﻋﺗﻼل اﻟﺗﺟﻠط &nbsp;اﻻﺳﺗﮭﻼﻛﻲ، ھو ﺣﺎﻟﺔ ﺗﮭدد اﻟﺣﯾﺎة وﻓﯾﮭﺎ ﯾﺣدث ﺗﺟﻠط ﻣﻔرط ﻟﻠدم ﻣﻊ ﺗﻛون واﺿﺢ ﻟﻠﺟﻠطﺎت اﻟدﻣوﯾﺔ داﺧل اﻷوﻋﯾﺔ &nbsp;اﻟدﻣوﯾﺔ. ﯾؤدي ذﻟك ﺑدوره إﻟﻰ اﺳﺗﮭﻼك ﻋواﻣل اﻟﺗﺟﻠط ﻓﻲ اﻟﺟﺳم ﺑﺄﻛﻣﻠﮫ(&nbsp;<br />ﻓﻲ ﺣﺎﻟﺔ اﺣﺗﺷﺎء ﻋﺿﻠﺔ اﻟﻘﻠب و/أو اﻟﺗﺧﺛر اﻟﺣﺎد و/أو اﻻﻧﺻﻣﺎم: ﻻ ﯾﻧﺑﻐﻲ اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( ﺳوى ﻓﻲ ﺣﺎﻻت ﻧوﺑﺎت اﻟﻧزﯾف اﻟﺗﻲ ﺗﮭدد اﻟﺣﯾﺎة. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ﺗﺣذﯾرات واﺣﺗﯾﺎطﺎت&nbsp;<br />ﺗﺣدث إﻟﻰ طﺑﯾﺑك ﻗﺑل اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA(، ﻷن ﺗﻔﺎﻋﻼت ﻓرط اﻟﺣﺳﺎﺳﯾﺔ ﻗد ﺗﺣدث، ﻛﻣﺎ ھو اﻟﺣﺎل ﻣﻊ ﻛل ﻣﻧﺗﺟﺎت اﻟﺑﻼزﻣﺎ اﻟﺗﻲ ﺗﻌُ طﻰ ﻋن طرﯾﻖ اﻟورﯾد. وﻟﺗﺗﻣﻛن ﻣن اﻟﺗﻌرف ﻋﻠﻰ اﻟﺗﻔﺎﻋل اﻟﺣﺳﺎﺳﻲ ﻓﻲ أﻗرب وﻗت ﻣﻣﻛن ﻣن ﺣدوﺛﮫ، ﻋﻠﯾك أن ﺗﻛون &nbsp;ﻋﻠﻰ دراﯾﺔ ﺑﺎﻷﻋراض اﻟﻣﺑﻛرة اﻟﻣﺣﺗﻣﻠﺔ ﻟﺗﻔﺎﻋل ﻓرط اﻟﺣﺳﺎﺳﯾﺔ وﻣﻧﮭﺎ ﻣﺎ ﯾﻠﻲ: &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;اﻟﺣﻣﺎﻣﻰ )اﺣﻣرار اﻟﺟﻠد(&nbsp;<br />اﻟطﻔﺢ اﻟﺟﻠدي &nbsp;<br />ﺣدوث ﺷري )طﻔﺢ ﺟﻠدي ﻗراﺻﻲ/أرﺗﯾﻛﺎرﯾﺎ( ﻋﻠﻰ اﻟﺟﻠد &nbsp;اﻟﺣﻛﺔ ﻓﻲ ﻛﺎﻓﺔ أﻧﺣﺎء اﻟﺟﺳم &nbsp;<br />&nbsp;ﺗورّ م اﻟﺷﻔﺗﯾن واﻟﻠﺳﺎن &nbsp;<br />&nbsp;ﺻﻌوﺑﺔ اﻟﺗﻧﻔس/ﻋﺳر اﻟﺗﻧﻔس&nbsp;<br />&nbsp;ﺿﯾﻖ اﻟﺻدر &nbsp;<br />&nbsp;اﻟﺗوﻋك اﻟﻌﺎم &nbsp;<br />&nbsp;اﻟﺷﻌور ﺑدوﺧﺔ&nbsp;<br />&nbsp;اﻧﺧﻔﺎض ﺿﻐط اﻟدم &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ﺗﺗﺿﻣن اﻷﻋراض اﻷﺧرى ﻟﺗﻔﺎﻋﻼت ﻓرط اﻟﺣﺳﺎﺳﯾﺔ ﻟﻠﻣﻧﺗﺟﺎت اﻟﻣﺷﺗﻘﺔ ﻣن اﻟﺑﻼزﻣﺎ اﻟﺧﻣول واﻟﺗﻣﻠﻣل. &nbsp;إن ﻻﺣظت واﺣدًا أو أﻛﺛر ﻣن ھذه اﻷﻋراض، ﻓﺄوﻗف اﻟﺗﺳرﯾب ﻓورً ا واﺗﺻل ﺑطﺑﯾﺑك ﺑﺄﺳرع ﻣﺎ ﯾﻣﻛن. ﻗد ﺗﻣﺛل اﻷﻋراض &nbsp;اﻟﻣذﻛورة أﻋﻼه ﻣؤﺷرات ﻣﺑﻛرة ﻟﺻدﻣﺔ ﺗﺄﻗﯾﺔ. ﺗﺗطﻠب اﻷﻋراض اﻟﺷدﯾدة ﻋﻼﺟًﺎ طﺎرﺋﺎ ﻓً ورﯾﺎً &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﻟن ﯾﺳﺗﺧدم اﻟطﺑﯾب ﻓﺎﯾﺑﺎ )FEIBA( ﻣرة أﺧرى ﻓﻲ ﺣﺎﻟﺔ اﻟﻣرﺿﻰ اﻟﻣﺷﺗﺑﮫ ﻓﻲ إﺻﺎﺑﺗﮭم ﺑﻔرط اﻟﺣﺳﺎﺳﯾﺔ ﺗﺟﺎه اﻟﻣﻧﺗﺞ أو أي ﻣن &nbsp;ﻣﻛوﻧﺎﺗﮫ إﻻ ﺑﻌد اﻟﻣوازﻧﺔ ﺑﻌﻧﺎﯾﺔ ﺑﯾن اﻟﻣﻧﺎﻓﻊ واﻟﻣﺧﺎطر اﻟﻣﺗوﻗﻌﺔ ﻹﻋﺎدة اﻟﺗﻌرض و/أو ﺗوﻗﻊ ﻋدم ﺻدور ﺗﻔﺎﻋل ﻋن ﻋﻼج وﻗﺎﺋﻲ &nbsp;آﺧر أو ﻋﻘﺎﻗﯾر ﻋﻼﺟﯾﺔ ﺑدﯾﻠﺔ&nbsp;<br />إن أﺻﺎﺑﺗك ﺗﻐﯾرات ﻛﺑرى ﻓﻲ ﺿﻐط اﻟدم أو ﻣﻌدل اﻟﻧﺑض، أو ﺻﻌوﺑﺎت ﻓﻲ اﻟﺗﻧﻔس، أو اﻟﺳﻌﺎل أو أﻟم اﻟﺻدر، ﻓﺄوﻗف &nbsp;اﻟﺗﺳرﯾب ﻓورً ا واﺗﺻل ﺑطﺑﯾﺑك. ﺳﯾﺑﺎﺷر طﺑﯾﺑك اﻹﺟراءات اﻟﺗﺷﺧﯾﺻﯾﺔ واﻟﻌﻼﺟﯾﺔ اﻟﻣﻼﺋﻣﺔ.&nbsp;<br />ﻓﻲ ﺣﺎﻟﺔ ﻣرﺿﻰ اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ ذوي اﻟﻣﺛﺑطﺎت أو اﻟﻣﺛﺑطﺎت اﻟﻣﻛﺗﺳﺑﺔ ﺗﺟﺎه ﻋواﻣل اﻟﺗﺟﻠط. &nbsp;ﻓﻲ ﺣﺎﻟﺔ ﺧﺿوﻋﮭم ﻟﻠﻌﻼج &nbsp;ﺑﺎﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA(، ﻓﺈن ھؤﻻء اﻟﻣرﺿﻰ ﺳﯾﻛوﻧون أﻛﺛر ﻗﺎﺑﻠﯾﺔ ﻟﻠﻧزﯾف وأﻛﺛر ﻋرﺿﺔ ﻟﺧطر اﻟﺗﺧﺛر ﻓﻲ ﻧﻔس اﻟوﻗت<br />ﺳﺑﻖ أن ﺣدﺛت ﺣﺎﻻت ﺗﺧﺛرﯾﺔ وﺗﺧﺛرﯾﺔ اﻧﺻﻣﺎﻣﯾﺔ ﺧﻼل اﻟﻌﻼج ﺑﺎﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA(، ﺑﻣﺎ ﻓﻲ ذﻟك اﻟﺗﺟﻠط اﻟﻣﻧﺗﺷر داﺧل اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ )DIC(، واﻟﺗﺧﺛر اﻟورﯾدي، واﻻﻧﺻﻣﺎم اﻟرﺋوي، واﺣﺗﺷﺎء ﻋﺿﻠﺔ اﻟﻘﻠب، واﻟﺳﻛﺗﺔ اﻟدﻣﺎﻏﯾﺔ. وﯾرﺟﺢ أن ﯾؤدي &nbsp;اﻻﺳﺗﺧدام اﻟﻣﺗزاﻣن ﻟﻠﻌﺎﻣل اﻟﻣﺄﺷوب 7أ )VIIa( إﻟﻰ زﯾﺎدة ﺧطر ﺣدوث ﺣﺎﻟﺔ ﺗﺧﺛرﯾﺔ اﻧﺻﻣﺎﻣﯾﺔ. ﺣدﺛت ﺑﻌض اﻟﺣﺎﻻت اﻟﺗﺧﺛرﯾﺔ اﻻﻧﺻﻣﺎﻣﯾﺔ ﻓﻲ ﺣﺎﻟﺔ اﻟﻌﻼج ﺑﺟرﻋﺎت ﻋﺎﻟﯾﺔ ﻣن ﻓﺎﯾﺑﺎ )FEIBA(.&nbsp;<br />ﻓﻲ دراﺳﺔ أﺟرﺗﮭﺎ ﺷرﻛﺔ أﺧرى ﻟﺗﻘﯾﯾم دواء إﻣﯾﺳﯾزوﻣﺎب )دواء ﻟﻠوﻗﺎﯾﺔ ﻣن اﻟﻧزﯾف ﻟدى اﻟﻣﺻﺎﺑﯾن ﺑﺎﻟﮭﯾﻣوﻓﯾﻠﯾﺎ أ(، ﺧﺿﻊ ﺑﻌض اﻟﻣرﺿﻰ اﻟذﯾن ﺗﻌرﺿوا ﻟﺣﺎﻻت ﻧزﯾف اﺧﺗراﻗﻲ ﻟﻠﻌﻼج ﺑﻔﺎﯾﺑﺎ )FEIBA( ﻟﻠﺳﯾطرة ﻋﻠﻰ اﻟﻧزﯾف، وأﺻﯾﺑت ﻗﻠﺔ ﻣن ھؤﻻء اﻟﻣرﺿﻰ ﺑﺎﻋﺗﻼل اﻷوﻋﯾﺔ اﻟدﻗﯾﻘﺔ اﻟﺧﺛﺎري )TMA(. واﻋﺗﻼل اﻷوﻋﯾﺔ اﻟﺧﺛﺎري ﺣﺎﻟﺔ ﺧطﯾرة ورﺑﻣﺎ ﺗﮭدد ﺣﯾﺎة اﻟﻣرﯾض. ﻋﻧد اﻹﺻﺎﺑﺔ ﺑﮭذه اﻟﺣﺎﻟﺔ، ﯾﻣﻛن أن ﺗﺗﻌرض ﺑطﺎﻧﺔ اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ ﻟﻠﺗﻠف ورﺑﻣﺎ ﺗﺗﻛون ﺗﺟﻠطﺎت دم ﻓﻲ اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ اﻟﺻﻐﯾرة. وﻓﻲ ﺑﻌض اﻟﺣﺎﻻت، ﻗد ﺗﺳﺑب ھذه اﻟﺣﺎﻟﺔ ﺗﻠﻔًﺎ ﻓﻲ اﻟﻛﻠﻰ واﻷﻋﺿﺎء اﻷﺧرى. وﻓﻲ ﺣﺎﻻت اﻟﻧزﯾف اﻻﺧﺗراﻗﻲ أﺛﻧﺎء اﻟﻣواظﺑﺔ ﻋﻠﻰ &nbsp;اﻟﻌﻼج اﻟوﻗﺎﺋﻲ إﻣﯾﺳﯾزوﻣﺎب، ﯾﻧﺑﻐﻲ اﻻﺗﺻﺎل ﺑﺎﻟطﺑﯾب اﻟﻣﻌﺎﻟﺞ ﻟﺣﺎﻟﺔ اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ أو ﻣرﻛز ﻋﻼج اﻟﮭﯾﻣوﻓﯾﻠﯾﺎ ﻋﻠﻰ اﻟﻔور. &nbsp;.&nbsp;<br />ﻋﻧدﻣﺎ ﯾﺗم ﺗﺻﻧﯾﻊ اﻷدوﯾﺔ ﻣن اﻟدم أو اﻟﺑﻼزﻣﺎ اﻟﺑﺷرﯾﺔ، ﯾﺗم اﺗﺧﺎذ ﺑﻌض اﻹﺟراءات ﻟﻣﻧﻊ اﻧﺗﻘﺎل اﻟﻌدوى إﻟﻰ اﻟﻣرﺿﻰ. وﺗﺷﻣل &nbsp;ھذه اﻹﺟراءات اﻧﺗﻘﺎء اﻟﻣﺗﺑرﻋﯾن ﺑﺎﻟدم واﻟﺑﻼزﻣﺎ ﺑدﻗﺔ ﻟﻠﺗﺄﻛد ﻣن اﺳﺗﺑﻌﺎد اﻷﺷﺧﺎص اﻟﺣﺎﻣﻠﯾن ﻟﺧطر اﻟﻌدوى، ﺛم اﺧﺗﺑﺎر ﻛل ﺗﺑرع وﺗﺟﻣﯾﻌﺎت اﻟﺑﻼزﻣﺎ ﺑﺣﺛﺎً ﻋن وﺟود ﻋﻼﻣﺎت ﻋﻠﻰ ﻓﯾروس/ﻋدوى. &nbsp;ﻛﻣﺎ ﺗﺣرص اﻟﺷرﻛﺎت اﻟﻣﺻﻧﻌﺔ ﻟﮭذه اﻟﻣﻧﺗﺟﺎت ﻋﻠﻰ إدراج &nbsp;ﺧطوات ﻓﻲ ﻋﻣﻠﯾﺔ ﻣﻌﺎﻟﺟﺔ اﻟدم واﻟﺑﻼزﻣﺎ ﺗﺗﯾﺢ ﺗﻌطﯾل ﻧﺷﺎط اﻟﻔﯾروﺳﺎت أو اﻟﺗﺧﻠص ﻣﻧﮭﺎ. وﻋﻠﻰ اﻟرﻏم ﻣن اﺗﺧﺎذ ﻛل ھذه &nbsp;اﻟﺗداﺑﯾر، إﻻ أﻧﮫ ﻋﻧد اﺳﺗﺧدام اﻷدوﯾﺔ اﻟﻣُﻌدّة ﻣن اﻟدم أو اﻟﺑﻼزﻣﺎ اﻟﺑﺷرﯾﺔ، ﻓﻼ ﯾﻣﻛن اﺳﺗﺑﻌﺎد إﻣﻛﺎﻧﯾﺔ اﻧﺗﻘﺎل اﻟﻌدوى ﺗﻣﺎﻣًﺎ. وھذا ﯾﻧطﺑﻖ أﯾﺿًﺎ ﻋﻠﻰ اﻟﻔﯾروﺳﺎت ﻏﯾر اﻟﻣﻌروﻓﺔ أو اﻟﻣﺳﺗﺟدة أو ﻏﯾرھﺎ ﻣن أﻧواع اﻟﻌدوى.&nbsp;<br />ﺗﻌﺗﺑر اﻟﺗداﺑﯾر اﻟﻣﺗﺧذة ﻓﻌّﺎﻟﺔ ﻟﻠﺑﺣث ﻋن اﻟﻔﯾروﺳﺎت اﻟﻣﻐﻠﻔﺔ ﻣﺛل ﻓﯾروس ﻧﻘص اﻟﻣﻧﺎﻋﺔ اﻟﺑﺷرﯾﺔ )HIV( وﻓﯾروس اﻟﺗﮭﺎب اﻟﻛﺑد ﺑﻲ&quot; وﻓﯾروس اﻟﺗﮭﺎب اﻟﻛﺑد اﻟوﺑﺎﺋﻲ &quot;ﺳﻲ&quot;، وﻓﯾروس اﻟﺗﮭﺎب اﻟﻛﺑد &quot;أ&quot;ﻏﯾر اﻟﻣﻐﻠف. ﻗد ﺗﻛون اﻟﺗداﺑﯾر اﻟﻣﺗﺧذة ذات ﻗﯾﻣﺔ ﻣﺣدودة &nbsp;ﺿد اﻟﻔﯾروﺳﺎت ﻏﯾر اﻟﻣﻐﻠﻔﺔ ﻣﺛل اﻟﻔﯾروس اﻟﺻﻐﯾر ب 19. ﻗد ﺗﻛون ﻋدوى اﻟﻔﯾروس اﻟﺻﻐﯾر ب 19 )B19( ﺧطﯾرة ﻟدى &nbsp;اﻟﻧﺳﺎء اﻟﺣواﻣل )ﻋدوى اﻟﺟﻧﯾن( وﻟﻸﻓراد اﻟذﯾن ﯾﻌﺎﻧون ﻣن ﺗﺛﺑﯾط ﺑﺎﻟﺟﮭﺎز اﻟﻣﻧﺎﻋﻲ أو ﻣن ﺑﻌض أﻧواع ﻓﻘر اﻟدم )ﻣﺛل ﻣرض &nbsp;اﻟﺧﻼﯾﺎ اﻟﻣﻧﺟﻠﯾﺔ أو ﻓﻘر اﻟدم اﻻﻧﺣﻼﻟﻲ(. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ﻗد ﯾوﺻﯾك اﻟطﺑﯾب ﺑﺎﻟﺗﻔﻛﯾر ﻓﻲ اﻟﺣﺻول ﻋﻠﻰ ﺗطﻌﯾم ﺿد اﻟﺗﮭﺎب اﻟﻛﺑد &quot;أ&quot; و&quot;ب&quot; إذا ﻛﻧت ﺗﺗﻧﺎول ﻣﻧﺗﺟﺎت ﻣﺛﺑطﺎت اﻟﻌﺎﻣل اﻟﺛﺎﻣن اﻟﻣﺷﺗﻘﺔ ﻣن اﻟﺑﻼزﻣﺎ اﻟﺑﺷرﯾﺔ ﻋﻠﻰ ﻧﺣو ﻣﻧﺗظم أو ﻣﺗﻛرر. &nbsp;<br />ﺑﻌد إﻋطﺎء ﺟرﻋﺎت ﻋﺎﻟﯾﺔ ﻣن ﻓﺎﯾﺑﺎ )FEIBA(، ﻓﺈن اﻻرﺗﻔﺎع اﻟﻌﺎﺑر ﻟﻸﺟﺳﺎم اﻟﻣﺿﺎدة اﻟﺳطﺣﯾﺔ ﻟﻔﯾروس اﻟﺗﮭﺎب اﻟﻛﺑد &quot;ب&quot; اﻟﻣﻧﻘوﻟﺔ ﺳﻠﺑﯾًﺎ ﻗد ﯾؤدي إﻟﻰ ﺗﻔﺳﯾر ﻣﺿﻠل ﻟﻠﻧﺗﺎﺋﺞ اﻹﯾﺟﺎﺑﯾﺔ ﺿﻣن اﻻﺧﺗﺑﺎرات اﻟﻣﺻﻠﯾﺔ.&nbsp;<br />ﻓﺎﯾﺑﺎ )FEIBA( ﻣﻧﺗﺞ ﻣﺷﺗﻖ ﻣن اﻟﺑﻼزﻣﺎ وﻗد ﯾﺣﺗوي ﻋﻠﻰ ﻣواد ﺗﺗﻔﺎﻋل ﻣﻊ اﻟﻣﺎدة اﻟﺗﻲ ﯾﺗم ﺗﺳرﯾﺑﮭﺎ ﻓﻲ أﺟﺳﺎم اﻟﻣرﺿﻰ، ﻣﻣﺎ ﯾﺳﺑب راﺻﺎت دﻣوﯾﺔ إﺳوﯾﺔ )وھﻲ أﺟﺳﺎم ﻣﺿﺎدة ﺗﺳﺑب اﻟﺗﺻﺎق ﺧﻼﯾﺎ اﻟدم اﻟﺣﻣراء اﻟﻣﺄﺧوذة ﻣن ﺷﺧص آﺧر(. ﻗد ﺗؤدي ھذه &nbsp;اﻟﻌﻣﻠﯾﺔ إﻟﻰ ﻧﺗﺎﺋﺞ ﻣﺿﻠﻠﺔ ﻓﻲ اﺧﺗﺑﺎرات اﻟدم .<br />وﯾوﺻﻰ ﺑﺷدة ﺑﺗﺳﺟﯾل اﺳم اﻟﻣﻧﺗﺞ ورﻗم اﻟدﻓﻌﺔ ﻓﻲ ﻛل ﻣرة ﺗﺗﻠﻘﻰ ﻓﯾﮭﺎ ﺟرﻋﺔ ﻣن ﻓﺎﯾﺑﺎ )FEIBA( ﻟﻠﺣﻔﺎظ ﻋﻠﻰ ﺳﺟل ﺑﺎﻟدﻓﻌﺎت اﻟﻣﺳﺗﺧدﻣﺔ. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; اﺳﺗﺧدام اﻷدوﯾﺔ اﻷﺧرى ﻣﻊ ﻓﺎﯾﺑﺎ )FEIBA( &nbsp;ﯾرُ ﺟﻰ إﺧﺑﺎر اﻟطﺑﯾب أو اﻟﺻﯾدﻻﻧﻲ ﻓﻲ ﺣﺎﻟﺔ ﺗﻧﺎول أدوﯾﺔ أﺧرى ﻣؤﺧرً ا أو ﻓﻲ اﻟوﻗت اﻟﺣﺎﻟﻲ، ﺑﻣﺎ ﻓﻲ ذﻟك اﻷدوﯾﺔ اﻟﺗﻲ ﺗﺻرف &nbsp;دون وﺻﻔﺔ طﺑﯾﺔ. &nbsp; &nbsp; &nbsp; &nbsp; ﻟم ﺗﺟُ رى دراﺳﺎت ﻣﻼﺋﻣﺔ وﻣﺣﻛﻣﺔ ﺟﯾدًا ﺑﺧﺻوص اﻻﺳﺗﺧدام اﻟﻣﺷﺗرك أو اﻟﺗﺳﻠﺳﻠﻲ ﻟدواء ﻓﺎﯾﺑﺎ )FEIBA( واﻟﻌﺎﻣل 7أ )VIIa( اﻟﻣﺄﺷوب أو ﻣﺿﺎدات اﻧﺣﻼل اﻟﻔﯾﺑرﯾن أو إﻣﯾﺳﯾزوﻣﺎب. ﯾﻧﺑﻐﻲ ﻣراﻋﺎة اﺣﺗﻣﺎﻟﯾﺔ ﺣدوث ﺣﺎﻻت ﺗﺧﺛرﯾﺔ ﻋﻧد اﺳﺗﺧدام &nbsp;ﻣﺿﺎدات اﻧﺣﻼل اﻟﻔﯾﺑرﯾن اﻟﺟﮭﺎزﯾﺔ ﻣﺛل ﺣﻣض اﻟﺗراﻧﯾﻛﺳﺎﻣﯾك وﺣﻣض اﻷﻣﯾﻧوﻛﺎﺑروﯾك ﺧﻼل اﻟﻌﻼج ﺑﺎﺳﺗﺧدام ﻓﺎﯾﺑﺎ&nbsp;<br />)FEIBA(. وﻋﻠﻰ ذﻟك، ﻻ ﯾﻧﺑﻐﻲ اﺳﺗﺧدام ﻣﺿﺎدات اﻧﺣﻼل اﻟﻔﯾﺑرﯾن ﻟﻣدة 6 ﺳﺎﻋﺎت إﻟﻰ 12 ﺳﺎﻋﺔ ﺗﻘرﯾﺑًﺎ ﺑﻌد إﻋطﺎء ﻓﺎﯾﺑﺎ )FEIBA(. ﻓﻲ ﺣﺎﻻت اﻻﺳﺗﺧدام اﻟﻣﺗزاﻣن ﻟﻠﻌﺎﻣل 7أ )VIIa( اﻟﻣﺄﺷوب، ﻻ ﯾﻣﻛن اﺳﺗﺑﻌﺎد ﺣدوث ﺗﻔﺎﻋل دواﺋﻲ ﻣﺣﺗﻣل ﺑﻧﺎءً ﻋﻠﻰ اﻟﺑﯾﺎﻧﺎت اﻟﻣﻌﻣﻠﯾﺔ اﻟﻣﺗﺎﺣﺔ واﻟﻣﻼﺣظﺎت اﻟﺳرﯾرﯾﺔ، وھو ﻣﺎ ﯾﺣﺗﻣل أن ﯾؤدي إﻟﻰ ﺣدوث ﺣﺎﻟﺔ ﺗﺧﺛرﯾﺔ اﻧﺻﻣﺎﻣﯾﺔ. ﯾﻧﺑﻐﻲ إﺧﺑﺎر اﻟطﺑﯾب إذا ﻛﻧت ﺳﺗﺗﻠﻘﻰ اﻟﻌﻼج ﺑﻔﺎﯾﺑﺎ )FEIBA( ﺑﻌد ﺗﻠﻘﻲ إﻣﯾﺳﯾزوﻣﺎب )ﻋﻼج ﻟﻠوﻗﺎﯾﺔ ﻣن اﻟﻧزﯾف ﻟدى اﻟﻣﺻﺎﺑﯾن ﺑﺎﻟﮭﯾﻣوﻓﯾﻠﯾﺎ أ( ﻷﻧﮫ ﺗوﺟد ﺗﺣذﯾرات واﺣﺗﯾﺎطﺎت ﯾﺟب ﻣراﻋﺎﺗﮭﺎ. ﺳﯾﺣﺗﺎج اﻟطﺑﯾب إﻟﻰ ﻣراﻗﺑﺔ اﻟﻣرﯾض ﻋن ﻛﺛب. &nbsp;&nbsp;<br />ﻛﻣﺎ ھو اﻟﺣﺎل ﻣﻊ ﻛل ﻣﺳﺗﺣﺿرات اﻟﺗﺟﻠط، ﻻ ﯾﻧﺑﻐﻲ ﺧﻠط ﻓﺎﯾﺑﺎ )FEIBA( ﺑﻐﯾره ﻣن اﻟﻣﻧﺗﺟﺎت اﻟدواﺋﯾﺔ ﻗﺑل إﻋطﺎﺋﮫ، ﺣﯾث ﻗد &nbsp;ﯾﻌوق ذﻟك ﻓﺎﻋﻠﯾﺔ اﻟﻣﺳﺗﺣﺿر وﺗﺣﻣﻠﮫ. &nbsp;<br />ﯾﻧُ ﺻﺢ ﺑﺷطف وﺻﻠﺔ اﻟﺗﺳرﯾب اﻟورﯾدي اﻟﻣﺷﺗرﻛﺔ ﺑﻣﺣﻠول ﻣﻠﺣﻲ ﻓﺳﯾوﻟوﺟﻲ ﻗﺑل إﻋطﺎء ﻓﺎﯾﺑﺎ )FEIBA( وﺑﻌده. &nbsp; اﻟﺣﻣل واﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ واﻟﺧﺻوﺑﺔ&nbsp;<br />ﺳوف ﯾﻘرر طﺑﯾﺑك إذا ﻛﺎن ﯾﻣﻛن اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( أﺛﻧﺎء اﻟﺣﻣل واﻟرﺿﺎﻋﺔ أم ﻻ. ﻧظرً ا إﻟﻰ زﯾﺎدة ﺧطر اﻟﺗﺧﺛر ﺧﻼل &nbsp;اﻟﺣﻣل، ﻓﻼ ﯾﻧﺑﻐﻲ إﻋطﺎء ﻓﺎﯾﺑﺎ )FEIBA( إﻻ ﺗﺣت اﻟﻣراﻗﺑﺔ اﻟطﺑﯾﺔ اﻟدﻗﯾﻘﺔ وﻓﻘط ﻓﻲ ﺣﺎﻟﺔ وﺟود ﺿرورة ﺣﺗﻣﯾﺔ ﻟذﻟك. ﺗﺗوﻓر اﻟﻣﻌﻠوﻣﺎت اﻟﺧﺎﺻﺔ ﺑﻌدوى اﻟﻔﯾروس اﻟﺻﻐﯾر ب 19 )Ba19( ﻓﻲ ﻗﺳم اﻟﺗﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت. ﯾلقيادة واﺳﺗﺧدام اﻵﻻت&nbsp;<br />ﻻ ﺗوﺟد ﻋﻼﻣﺎت أن ﻓﺎﯾﺑﺎ )FEIBA( ﻗد ﯾؤﺛر ﻋﻠﻰ اﻟﻘدرة ﻋﻠﻰ اﻟﻘﯾﺎدة أو اﺳﺗﺧدام اﻵﻻت. &nbsp;معلومات ھﺎﻣﺔ ﻋن ﺑﻌض ﻣﻛوﻧﺎت ﻓﺎﯾﺑﺎ )FEIBA(&nbsp;<br />ﯾﺣﺗوي ﻓﺎﯾﺑﯾﺎ ﺑﺟرﻋﺔ 50 وﺣدة/ﻣﻠﻠﻲ ﻋﻠﻰ 4 ﻣﻠﻠﯾﺟرام ﺻودﯾوم ﺗﻘرﯾﺑًﺎ )ﻣﺣﺳوب( ﻟﻛل ﻣﻠﻠﻲ، وﯾﺣﺗوي ﺗﻘرﯾﺑًﺎ ﻋﻠﻰ 40 ﻣﻠﻠﯾﺟرام &nbsp;ﻣن اﻟﺻودﯾوم ﻓﻲ اﻟﺟرﻋﺔ ذات &nbsp;500 وﺣدة، وﯾﺣﺗوي ﺗﻘرﯾﺑًﺎ ﻋﻠﻰ 80 ﻣﻠﻠﯾﺟرام ﺗﻘرﯾﺑًﺎ ﻣن اﻟﺻودﯾوم ﻓﻲ اﻟﺟرﻋﺔ ذات &nbsp; 1000 وﺣدة، وﯾﺣﺗوي ﺗﻘرﯾﺑًﺎ ﻋﻠﻰ 200 ﻣﻠﻠﯾﺟرام ﻣن اﻟﺻودﯾوم ﻓﻲ اﻟﺟرﻋﺔ ذات 2500 وﺣدة. ﯾﻧﺑﻐﻲ ﻣراﻋﺎة ذﻟك ﻓﻲ ﺣﺎﻟﺔ اﻟﻣرﺿﻰ &nbsp;اﻟذﯾن ﯾﺧﺿﻌون ﻟﻧظﺎم ﻏذاﺋﻲ ﻗﻠﯾل اﻟﺻودﯾوم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أذب ﻣﺳﺣوق ﻓﺎﯾﺑﺎ )FEIBA( اﻟﻣﺟﻔف ﺑﺎﻟﺗﺟﻣﯾد ﻣﻊ اﻟﻣذﯾب اﻟﻣرﻓﻖ ﺑﺎﻟﻌﺑوة وأﻋطِ اﻟﻣﺣﻠول ﻋن طرﯾﻖ اﻟورﯾد. &nbsp;اﺣرص دوﻣًﺎ ﻋﻠﻰ اﺳﺗﺧدام ﻓﺎﯾﺑﺎ )FEIBA( ﺗﻣﺎﻣًﺎ ﻛﻣﺎ أﺧﺑرك طﺑﯾﺑك. ﯾﺟب اﺳﺗﺷﺎرة اﻟطﺑﯾب إذا ﻟم ﺗﻛن ﻣﺗﺄﻛدًا. &nbsp;ﻧظرً ا إﻟﻰ ﺷدة ﻣﺎ ﺗﻌﺎﻧﯾﮫ ﻣن اﺿطراب ﻟﺗﺟﻠط اﻟدم، وﺑﺳﺑب ﻣوﻗﻊ اﻟﻧزﯾف وﻧطﺎﻗﮫ وﺣﺎﻟﺗك اﻟﻌﺎﻣﺔ واﺳﺗﺟﺎﺑﺗك ﻟﻠﻣﺳﺗﺣﺿر، ﻓﻘد ﻗرر طﺑﯾﺑك اﻟﺟرﻋﺔ واﻟﻔواﺻل اﻟزﻣﻧﯾﺔ اﻟﻣطﻠوﺑﺔ ﺑﯾن اﻟﺟرﻋﺎت ﺑﺎﻟﺷﻛل اﻟﻣطﻠوب ﻟك ﺷﺧﺻﯾﺎً . ﻻ ﺗﻐﯾر اﻟﺟرﻋﺎت اﻟﺗﻲ ﻗررھﺎ &nbsp;طﺑﯾﺑك وﻻ ﺗوﻗف اﺳﺗﺧدام اﻟﻣﺳﺗﺣﺿر ﻣن ﺗﻠﻘﺎء ﻧﻔﺳك. &nbsp;ﯾرﺟﻰ اﻟﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﺎن ﻟدﯾك اﻧطﺑﺎع ﺑﺄن ﺗﺄﺛﯾر ﻓﺎﯾﺑﺎ )FEIBA( أﻗوى أو أﺿﻌف ﻣﻣﺎ ﯾﻧﺑﻐﻲ. ﯾﺟب ﺗدﻓﺋﺔ اﻟﻣﻧﺗﺞ إﻟﻰ درﺟﺔ ﺣرارة اﻟﻐرﻓﺔ أو اﻟﺟﺳم ﻗﺑل اﻻﺳﺗﻌﻣﺎل ﻋﻧد اﻟﻠزوم . &nbsp;ﯾﺟب إذاﺑﺔ ﻓﺎﯾﺑﺎ )FEIBA( ﻣﺑﺎﺷرةً ﻗﺑل اﻻﺳﺗﻌﻣﺎل. ﯾﺟب اﺳﺗﺧدام اﻟﻣﺣﻠول ﻋﻠﻰ اﻟﻔور )ﺣﯾث إن اﻟﻣﺳﺗﺣﺿر ﻻ ﯾﺣﺗوي ﻋﻠﻰ ﻣواد ﺣﺎﻓظﺔ(&nbsp;<br />ﻗم ﺑﺎﻟﮭز ﺑرﻓﻖ إﻟﻰ أن ﺗذوب ﻛل &nbsp;اﻟﻣﺎدة. اﺣرص ﻋﻠﻰ أن ﯾذوب ﻓﺎﯾﺑﺎ )FEIBA( ﺗﻣﺎﻣًﺎ وإﻻ ﺳﯾﻣر ﻋدد أﻗل ﻣن وﺣدات ﻓﺎﯾﺑﺎ )FEIBA( ﻋﺑر ﻣرﺷﺢ اﻟﺟﮭﺎز &nbsp; &nbsp;. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﯾﻧﺑﻐﻲ اﻟﺗﺧﻠص ﻣن اﻟﻣﺣﺎﻟﯾل اﻟﻌﻛرة أو ذات اﻟﺷواﺋب ﺑﺷﻛل ﺳﻠﯾم. &nbsp;<br />ﻻ ﺗﻌُ د اﺳﺗﺧدام اﻟﺣﺎوﯾﺎت اﻟﻣﻔﺗوﺣﺔ. &nbsp; &nbsp;<br />ﻻ ﺗﺳﺗﺧدم ﺳوى ﻣﺎء اﻟﺣﻘن اﻟﻣرﻓﻖ ﺑﺎﻟﻌﺑوة واﻟﺟﮭﺎز اﻟﻣرﻓﻖ ﺑﮭﺎ اﻟﻣﮭﯾﺄ ﻹذاﺑﺔ اﻟﻣﺣﻠول. &nbsp;ﻓﻲ ﺣﺎﻟﺔ اﺳﺗﺧدام أﺟﮭزة ﺑﺧﻼف اﻷﺟﮭزة اﻟﻣرﻓﻘﺔ، ﻓﺎﺣرص ﻋﻠﻰ اﺳﺗﺧدام اﻟﻣرﺷﺢ اﻟﻣﻼﺋم ﻋﻠﻰ أن ﯾﻛون ﻣﻘﺎس ﻣﺳﺎﻣﮫ )ﺛﻘوﺑﮫ( 149 ﻣﯾﻛروﻣﺗر ﻋﻠﻰ اﻷﻗل. &nbsp; &nbsp; &nbsp;ﻻ ﺗﺳﺗﺧدم اﻟﻣﻧﺗﺞ إن ﺣدث ﺧرق ﻓﻲ ﺣﺎﺟزه اﻟواﻗﻲ اﻟﻣﻌﻘم، أو إن ﺗﺿررت ﻋﺑوﺗﮫ أو إن ظﮭرت ﻋﻠﯾﮫ ﻋﻼﻣﺎت اﻟﺗدھور ﯾﻧﺑﻐﻲ اﻟﺗﺧﻠص ﻣن أي ﻣﺳﺗﺣﺿر ﻏﯾر ﻣُﺳﺗﺧدم أو ﻧﻔﺎﯾﺎت ﺑﻣﺎ ﯾﺗﻣﺎﺷﻰ ﻣﻊ اﻟﻣﺗطﻠﺑﺎت اﻟﻣﺣﻠﯾﺔ. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إذاﺑﺔ اﻟﻣﺳﺣوق ﻹﻋداد اﻟﻣﺣﻠول ﻟﻠﺗﺳرﯾب ﺑﺎﺳﺗﺧدام ﺟﮭﺎز BAXJECT II Hi-Flow: the&nbsp;<br />1. &nbsp;دﻓﺊ ﻗﻧﯾﻧﺔ اﻟﻣذﯾب اﻟﻣﻐﻠﻘﺔ )اﻟﻣﺎء اﻟﻣﺧﺻص ﻟﻠﺣﻘن( ﺣﺗﻰ درﺟﺔ ﺣرارة اﻟﻐرﻓﺔ أو ﺑﺣد أﻗﺻﻰ ﺣﺗﻰ +37 درﺟﺔ ﻣﺋوﯾﺔ ﻋﻧد اﻟﻠزوم، ﻣﺛﻼً ﻋن طرﯾﻖ اﺳﺗﺧدام ﺣﻣﺎم ﻣﺎﺋﻲ ﻟﻌدة دﻗﺎﺋﻖ.&nbsp;<br />2. &nbsp;أزِ ل اﻷﻏطﯾﺔ اﻟواﻗﯾﺔ ﻣن ﻗﻧﯾﻧﺔ اﻟﻣﺳﺣوق وﻗﻧﯾﻧﺔ اﻟﻣذﯾب وطﮭر اﻟﺳدادات اﻟﻣطﺎطﯾﺔ ﻟﻛﻠﺗﯾﮭﻣﺎ. &nbsp;ﺿﻊ اﻟﻘﻧﯾﻧﺎت ﻋﻠﻰ ﺳطﺢٍ ﻣﺳﺗوٍ. 3. اﻓﺗﺢ ﻋﺑوة ﺟﮭﺎز BAXJECT II Hi-Flow ﻋن طرﯾﻖ ﺷد رﻗﺎﺋﻖ اﻷﻟوﻣوﻧﯾوم اﻟواﻗﯾﺔ دون ﻣﻼﻣﺳﺔ ﻣﺣﺗوﯾﺎت اﻟﻌﺑوة. ﻻ ﺗﻧزع ﻧظﺎم اﻟﻧﻘل ﻣن اﻟﻌﺑوة ﻓﻲ ﺗﻠك اﻟﻣرﺣﻠﺔ&nbsp;<br />4. &nbsp;اﻗﻠب اﻟﻌﺑوة رأﺳًﺎ ﻋﻠﻰ ﻋﻘب واﺿﻐط اﻟدﺑوس اﻟﺑﻼﺳﺗﯾﻛﻲ اﻟﺷﻔﺎف ﻋﺑر اﻟﺳدادة اﻟﻣطﺎطﯾﺔ ﻟﻘﻧﯾﻧﺔ اﻟﻣذﯾب . اﻧزع اﻵن اﻟﻌﺑوة ﻣن ﺟﮭﺎز BAXJECT II Hi-Flow )اﻟﺷﻛل ج(. ﻻ ﺗﻧزع اﻟﻐطﺎء اﻟواﻗﻲ اﻷزرق ﻣن ﺟﮭﺎز BAXJECT II Hi-Flowﻓﻲ ﺗﻠك اﻟﻣرﺣﻠﺔ. 5. واﻵن اﻗﻠب اﻟﻧظﺎم، اﻟﻣﻛون ﻣن ﺟﮭﺎز BAXJECT II Hi-Flow وﻗﻧﯾﻧﺔ اﻟﻣذﯾب، ﺑﺣﯾث ﺗﻛون ﻗﻧﯾﻧﺔ اﻟﻣذﯾب إﻟﻰ أﻋﻠﻰ. اﺿﻐط اﻟدﺑوس اﻟﻘرﻣزي ﺑﺟﮭﺎز BAXJECT II Hi-Flow ﻋﺑر ﻗﻧﯾﻧﺔ ﻓﺎﯾﺑﺎ )FEIBA(. ﯾﺗم ﺳﺣب اﻟﻣذﯾب إﻟﻰ ﻗﻧﯾﻧﺔ ﻓﺎﯾﺑﺎ )FEIBA( ﺑﺎﻟﺗﻔرﯾﻎ. &nbsp;6. &nbsp;ﻗم ﺑﺎﻟﮭز ﺑﻌﻧﺎﯾﺔ، ﻣﻊ ﺗوﺧﻲ اﻟﺣذر ﻣن رج اﻟﻧظﺎم ﺑﺎﻟﻛﺎﻣل، ﺣﺗﻰ ﯾذوب اﻟﻣﺳﺣوق. ﺗﺄﻛد أن ﻓﺎﯾﺑﺎ )FEIBA( ﻗد ذاب ﺑﺎﻟﻛﺎﻣل، ﻷﻧﮫ ﻗد ﯾﺣدث اﺣﺗﺑﺎس ﻟﻠﻣﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ اﻟﻧظﺎم ﺑﻔﻌل اﻟﻣرﺷﺢ. اﻟﺗﺳرﯾب (اﺳﺗﺧدم أﺳﺎﻟﯾب ﻣﻌﻘﻣﺔ طﯾﻠﺔ اﻹﺟراء). &nbsp; &nbsp; 1) ارﻓﻊ اﻟﻐطﺎء اﻟواﻗﻲ اﻷزرق ﻋن ﺟﮭﺎز BAXJECT II. ﻗم ﺑﺗوﺻﯾل اﻟﻣﺣﻘﻧﺔ ﺑﺟﮭﺎز BAXJECT II Hi-Flow ﻋﻠﻰ ﻧﺣو ﻣﺣﻛم. ﻻ ﺗﺳﺣب اﻟﮭواء إﻟﻰ اﻟﻣﺣﻘﻧﺔ. )اﻟﺷﻛل ھـ(. ﻟﻠﺗﺄﻛد ﻣن إﺣﻛﺎم ﺗوﺻﯾل اﻟﻣﺣﻘﻧﺔ ﺑﺟﮭﺎز &nbsp;BAXJECT II، ﯾوﺻﻰ ﺑﺷدة ﺑﺎﺳﺗﺧدام ﻣﺣﻘﻧﺔ ﻋﺎزﻟﺔ ﻟﻠﺗﺳرب )أدر اﻟﻣﺣﻘﻧﺔ ﻓﻲ اﺗﺟﺎه ﻋﻘﺎرب اﻟﺳﺎﻋﺔ ﺣﺗﻰ ﻣوﺿﻊ اﻹﯾﻘﺎف ﻋﻧد اﻟﺗﺛﺑﯾت(. &nbsp; &nbsp;2( اﻗﻠب اﻟﻧظﺎم ﺑﺣﯾث ﯾﻛون اﻟﻣﻧﺗﺞ اﻟذاﺋب إﻟﻰ أﻋﻠﻰ. اﺳﺣب اﻟﻣﻧﺗﺞ اﻟذاﺋب إﻟﻰ اﻟﻣﺣﻘﻧﺔ ﻋن طرﯾﻖ ﺳﺣب اﻟﻣﻛﺑس ﻟﻠﺧﻠف &nbsp;<br />ﺑﺑطء واﻟﺗﺄﻛد ﻣن إﺣﻛﺎم ﺗوﺻﯾل اﻟﻣﺣﻘﻧﺔ ﺑﺟﮭﺎز BAXJECT II طﯾﻠﺔ ﻋﻣﻠﯾﺔ اﻟﺳﺣب ﺑﺎﻟﻛﺎﻣل .&nbsp;<br />3( اﻓﺻل اﻟﻣﺣﻘﻧﺔ&nbsp;<br />&nbsp;(4( إن ﺣدﺛت رﻏوة ﻟﻠﻣﻧﺗﺞ داﺧل اﻟﻣﺣﻘن، ﻓﺎﻧﺗظر ﺣﺗﻰ زوال اﻟرﻏوة. &nbsp;أﻋطِ اﻟﻣﻧﺗﺞ ﻋﺑر اﻟورﯾد ﺑﺑطء ﺑﺎﺳﺗﺧدام ﻣﺟﻣوﻋﺔ اﻟﺗﺳرﯾب اﻟﻣرﻓﻘﺔ )أو اﻹﺑرة أﺣﺎدﯾﺔ اﻻﺳﺗﺧدام. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﻻ ﺗﺗﺟﺎوز ﻣﻌدل ﺗﺳرﯾب ﯾﺑﻠﻎ وﺣدﺗﯾن ﻣن ﻓﺎﯾﺑﺎ )FEIBA( ﻟﻛل ﻛﯾﻠوﺟرام ﻣن وزن اﻟﺟﺳم ﻓﻲ اﻟدﻗﯾﻘﺔ. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ﻓﻲ ﺣﺎﻟﺔ اﺳﺗﺧدام ﺟرﻋﺔ أﻛﺑر ﻣﻣﺎ ﯾﻧﺑﻐﻲ ﻣن ﻓﺎﯾﺑﺎ )FEIBA(: &nbsp;<br />ﯾرﺟﻰ إﺧطﺎر طﺑﯾﺑك ﻓورً ا. ﻗد ﺗؤدي اﻟﺟرﻋﺔ اﻟﻣﻔرطﺔ ﻣن ﻓﺎﯾﺑﺎ )FEIBA( إﻟﻰ زﯾﺎدة ﺧطر اﻵﺛﺎر ﻏﯾر اﻟﻣرﻏوﺑﺔ، ﻣﺛل &nbsp;اﻻﻧﺻﻣﺎم اﻟﺧﺛﺎري )ﺗﻛون ﺟﻠطﺔ دﻣوﯾﺔ ﻋﻧد دﻓﻊ اﻟﺗﺳرﯾب ﻓﻲ اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ( أو اﻋﺗﻼل اﻟﺗﺟﻠط اﻻﺳﺗﮭﻼﻛﻲ )اﻟﺗﺟﻠط اﻟﻣﻧﺗﺷر داﺧل اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ( أو اﺣﺗﺷﺎء ﻋﺿﻠﺔ اﻟﻘﻠب. ووﻓﻖ اﻟﺗﻘﺎرﯾر اﻟواردة ﻓﻲ ھذا اﻟﺷﺄن، ﺣدﺛت ﺑﻌض اﻟﺣﺎﻻت اﻻﻧﺻﻣﺎﻣﯾﺔ اﻟﺧﺛﺎرﯾﺔ ﻟدى ﺗﻧﺎول ﺟرﻋﺎت ﺗﻔوق 200 وﺣدة/ﻛﺟم أو ﻟدى اﻟﻣرﺿﻰ اﻟذﯾن ﻟدﯾﮭم ﻋواﻣل ﺧطر أﺧرى ﻟﻺﺻﺎﺑﺔ ﺑﺎﻟﺣﺎﻻت &nbsp;اﻻﻧﺻﻣﺎﻣﯾﺔ اﻟﺧﺛﺎرﯾﺔ. إن ﻟوﺣظت ﻋﻼﻣﺎت أو أﻋراض ﻟﻺﺻﺎﺑﺔ ﺑﺣﺎﻻت ﺧﺛﺎرﯾﺔ واﻧﺻﻣﺎﻣﯾﺔ ﺧﺛﺎرﯾﺔ، ﻓﯾﻧﺑﻐﻲ إﯾﻘﺎف اﻟﺗﺳرﯾب ﻓورً ا واﺗﺧﺎذ اﻹﺟراءات اﻟﺗﺷﺧﯾﺻﯾﺔ واﻟﻌﻼﺟﯾﺔ اﻟﻣﻼﺋﻣﺔ&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ﯾﻣﻛن أن ﯾﺗﺳﺑب ﻓﺎﯾﺑﺎ )FEIBA( ﻣﺛل ﺟﻣﯾﻊ اﻷدوﯾﺔ ﻓﻲ ﺣدوث آﺛﺎر ﺟﺎﻧﺑﯾﺔ، ﻋﻠﻰ اﻟرﻏم ﻣن ﻋدم ﺗﻌرض ﺟﻣﯾﻊ اﻟﻣرﺿﻰ ﻟﮭﺎ. &nbsp; &nbsp;اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺷﺎﺋﻌﺔ )ﻗد ﺗﺻﯾب ﻣرﯾض ﻣن ﻛل 10 ﻣرﺿﻰ(&nbsp;<br />ﻓرط اﻟﺣﺳﺎﺳﯾﺔ واﻟﺻداع واﻟدوﺧﺔ واﻧﺧﻔﺎض ﺿﻐط اﻟدم واﻟطﻔﺢ اﻟﺟﻠدي واﻟﻧﺗﯾﺟﺔ اﻹﯾﺟﺎﺑﯾﺔ ﻟﻠﺟﺳم اﻟﻣﺿﺎد اﻟﺳطﺣﻲ ﻟﻼﻟﺗﮭﺎب اﻟﻛﺑدي &quot;ب&quot;. آﺛﺎر ﺟﺎﻧﺑﯾﺔ ذات ﻣﻌدل ﺗواﺗر ﻏﯾر ﻣﻌروف )ﻻ ﯾﻣﻛن ﺗﻘدﯾر اﻟﺗواﺗر ﺑﻧﺎءً ﻋﻠﻰ اﻟﺑﯾﺎﻧﺎت اﻟﻣﺗﺎﺣﺔ( &nbsp;اﺿطراﺑﺎت ﻓﻲ اﻟدم واﻟﺟﮭﺎز اﻟﻠﻣﻔﺎوي: اﻋﺗﻼل اﻟﺗﺟﻠط اﻻﺳﺗﮭﻼﻛﻲ )اﻟﺗﺟﻠط اﻟﻣﻧﺗﺷر داﺧل اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ( وزﯾﺎدة ﻋﯾﺎر اﻟﻣﺛﺑط اﺿطراﺑﺎت اﻟﺟﮭﺎز اﻟﻣﻧﺎﻋﻲ: اﻟﺗﻔﺎﻋﻼت اﻟﺗﺄﻗﯾﺔ واﻟطﻔﺢ اﻟﺟﻠدي اﻟﻘراﺻﻲ ﻓﻲ اﻟﺟﺳم ﺑﺎﻟﻛﺎﻣل )اﻷرﺗﯾﻛﺎرﯾﺎ( &nbsp; اﺿطراﺑﺎت اﻟﺟﮭﺎز اﻟﻌﺻﺑﻲ: اﻟﺷﻌور ﺑﺎﻟﺧدَر )ﻧﻘص اﻹﺣﺳﺎس( ﻓﻲ اﻷطراف، واﺿطراب اﻹﺣﺳﺎس أو ﻧﻘﺻﮫ )اﻟﺗﻧﻣﯾل(، واﻟﺳﻛﺗﺔ اﻟدﻣﺎﻏﯾﺔ )اﻟﺳﻛﺗﺔ اﻟﺧﺛﺎرﯾﺔ واﻟﺳﻛﺗﺔ اﻻﻧﺻﻣﺎﻣﯾﺔ( واﻟﻧﻌﺎس )اﻟﻧوام( وﺗﺑدل ﺣﺎﺳﺔ اﻟﺗذوق )اﺿطراب ﺣﺎﺳﺔ اﻟﺗذوق( &nbsp; &nbsp;اﻻﺿطراﺑﺎت اﻟﻘﻠﺑﯾﺔ: اﻷزﻣﺔ اﻟﻘﻠﺑﯾﺔ )اﺣﺗﺷﺎء ﻋﺿﻠﺔ اﻟﻘﻠب( وﺧﻔﻘﺎن اﻟﻘﻠب )ﺗﺳﺎرع ﻧﺑض اﻟﻘﻠب( &nbsp; &nbsp; اﺿطراﺑﺎت اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ: ﺗﻛوّ ن ﺟﻠطﺔ دﻣوﯾﺔ ﻋﻧد دﻓﻊ اﻟﺗﺳرﯾب ﻓﻲ اﻷوﻋﯾﺔ اﻟدﻣوﯾﺔ )ﺣدوث ﺣﺎﻻت ﺧﺛﺎرﯾﺔ اﻧﺻﻣﺎﻣﯾﺔ وﺗﺧﺛر ورﯾدي وﺷرﯾﺎﻧﻲ(، وزﯾﺎدة ﺿﻐط اﻟدم )ارﺗﻔﺎع ﺿﻐط اﻟدم(، واﻟﺗورد &nbsp; &nbsp; &nbsp; اﺿطراﺑﺎت اﻟﺟﮭﺎز اﻟﺗﻧﻔﺳﻲ واﻟﺻدر واﻟﻣﻧﺻف )اﻟﻣﻧطﻘﺔ اﻟوﺳطﻰ ﻣن اﻟﺻدر(: اﻧﺳداد اﻟﺷرﯾﺎن اﻟرﺋوي )اﻻﻧﺻﻣﺎم اﻟرﺋوي( وﺿﯾﻖ اﻟﻣﺳﺎﻟك اﻟﮭواﺋﯾﺔ )ﺗﺷﻧﺞ اﻟﻘﺻﺑﺎت( واﻟﺻﻔﯾر اﻟﺗﻧﻔﺳﻲ واﻟﺳﻌﺎل واﻟﻠﮭﺎث )ﻋﺳر اﻟﺗﻧﻔس( &nbsp; &nbsp; اﺿطراﺑﺎت اﻟﻣﻌدة واﻷﻣﻌﺎء: اﻟﻘﻲء واﻹﺳﮭﺎل واﻻﻧزﻋﺎج ﻓﻲ اﻟﺑطن واﻟﺷﻌور ﺑﺎﻹﻋﯾﺎء )اﻟﻐﺛﯾﺎن( &nbsp; &nbsp; &nbsp; &nbsp;اﺿطراﺑﺎت اﻟﺟﻠد واﻟﻧﺳﯾﺞ ﺗﺣت اﻟﺟﻠد: اﻟﺷﻌور ﺑﺎﻟﺧدَر ﻓﻲ اﻟوﺟﮫ، وﺗورم اﻟوﺟﮫ واﻟﻠﺳﺎن واﻟﺷﻔﺗﯾن )اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ(، واﻟطﻔﺢ &nbsp;اﻟﺟﻠدي اﻟﻘراﺻﻲ ﻓﻲ اﻟﺟﺳم ﺑﺎﻟﻛﺎﻣل )اﻷرﺗﯾﻛﺎرﯾﺎ(، واﻟﺣﻛﺔ )اﻟﮭرش(&nbsp;<br />اﻻﺿطراﺑﺎت اﻟﻌﺎﻣﺔ واﻟﺷﻛﺎوى ﻓﻲ ﻣوﺿﻊ اﻟﺣﻘن: أﻟم ﻓﻲ ﻣوﺿﻊ اﻟﺣﻘن واﻟﺷﻌور اﻟﻌﺎم ﺑﺎﻹﻋﯾﺎء واﻟﺷﻌور ﺑﺎﻟﺳﺧوﻧﺔ واﻟﻘﺷﻌرﯾرة واﻟﺣﻣﻰ وأﻟم اﻟﺻدر واﻻﻧزﻋﺎج ﻓﻲ اﻟﺻدر &nbsp;اﻟﻔﺣوص: اﻧﺧﻔﺎض ﻓﻲ ﺿﻐط اﻟدم، ﯾﻣﻛن أن ﯾؤدي اﻟﺗﺳرﯾب اﻟﺳرﯾﻊ ﻓﻲ اﻟورﯾد إﻟﻰ أﻟم طﻌﻧﻲ وإﺣﺳﺎس ﺑﺎﻟﺗﻧﻣﯾل ﻓﻲ اﻟوﺟﮫ واﻷطراف، وﻛذﻟك إﻟﻰ اﻧﺧﻔﺎض ﺿﻐط اﻟدم. &nbsp;<br />ﻟوﺣظت اﺣﺗﺷﺎءات ﻋﺿﻠﺔ اﻟﻘﻠب ﺑﻌد إﻋطﺎء ﺟرﻋﺎت ﺗﻔوق اﻟﺟرﻋﺔ اﻟﯾوﻣﯾﺔ اﻟﻘﺻوى و/أو اﻻﺳﺗﺧدام ﻟﻔﺗرة طوﯾﻠﺔ و/أو وﺟود &nbsp;ﻋواﻣل ﺧطر ﻟﻼﻧﺻﻣﺎم اﻟﺧﺛﺎري&nbsp;<br />اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ&nbsp;<br />إذا أﺻُ ﺑت ﺑﺄي أﺛر ﺟﺎﻧﺑﻲ، ﻓﺗﺣدث ﻣﻊ طﺑﯾﺑك. ﯾﺷﻣل ھذا أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣﺣﺗﻣﻠﺔ ﻏﯾر ﻣدرﺟﺔ ﻓﻲ ھذه اﻟﻧﺷرة. ﯾﻣﻛﻧك اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ ﻣﺑﺎﺷرة ﻋﺑر ﻧظﺎم اﻹﺑﻼغ اﻟوطﻧﻲ ﻛﻣﺎ ھو ﻣوﺿﺢ أدﻧﺎه: &nbsp; اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ &nbsp;&nbsp;<br />&nbsp;اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ ))NPC +966-11-205-7662ﻓﺎﻛس: &nbsp;-2317 :+، اﻟرﻗم اﻟداﺧﻠﻲ966-11-2038222اﺗﺻل ﺑﺎﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ ﻋﻠﻰ رﻗم اﻻﺗﺻﺎل اﻟﮭﺎﺗﻔﻲ 2340-2356&nbsp;<br />اﻟﺧط اﻟﺳﺎﺧن اﻟﺧﺎص ﺑﺎﻹﺑﻼغ: 19999 اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ: npc.drug@sfda.gov.sa اﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ: www.sfda.gov.sa/npc &nbsp;دول ﻣﺟﻠس اﻟﺗﻌﺎون اﻟﺧﻠﯾﺟﻲ اﻷﺧرى &nbsp;ﯾرﺟﻰ اﻻﺗﺻﺎل ﺑﺎﻟﺳﻠ طﺔ اﻟﻣﺧﺗﺻﺔ ذات اﻟﺻﻠﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﯾﺣُ ﻔظ ﺑﻌﯾدًا ﻋن ﻣﺗﻧﺎول اﻷطﻔﺎل وﻣرآھم. &nbsp;ﻻ ﯾﺧزن ﻓﻲ درﺟﺔ ﺣرارة أﻋﻠﻰ ﻣن 25 درﺟﺔ ﻣﺋوﯾﺔ. ﻻ ﯾﺟﻣُ ﱠد. ﯾﺧزن ﻓﻲ ﻋﺑوﺗﮫ اﻷﺻﻠﯾﺔ ﻟﻠﺣﻣﺎﯾﺔ ﻣن اﻟﺿوء. &nbsp;ﻻ ﺗﺳﺗﺧدم ﻓﺎﯾﺑﺎ )FEIBA( ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣذﻛور ﻋﻠﻰ اﻟﻣﻠﺻﻖ واﻟﻌﻠﺑﺔ اﻟﻛرﺗوﻧﯾﺔ. ﯾﺷﯾر ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ &nbsp;إﻟﻰ آﺧر ﯾوم ﻣن اﻟﺷﮭر اﻟﻣذﻛور. ﯾﻧﺑﻐﻲ ﻋدم اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ ﻋﺑر ﻣﯾﺎه اﻟﺻرف أو ﻓﻲ اﻟﻘﻣﺎﻣﺔ اﻟﻣﻧزﻟﯾﺔ. اﺳﺄل اﻟﺻﯾدﻻﻧﻲ اﻟذي ﺗﺗﻌﺎﻣل ﻣﻌﮫ ﻋن طرﯾﻘﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﻓﻲ ﺣﺎﺟﺔ إﻟﯾﮭﺎ. ﺳﺗﺳﺎﻋد ھذه اﻟﺗداﺑﯾر ﻋﻠﻰ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﻣﺣﺗوﯾﺎت ﻓﺎﯾﺑﺎ 50 وﺣدة/ﻣل ﻣﺳﺣوق * اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ اﻟﻣوﺟودة ﻓﻲ اﻟﻘﻧﯾﻧﺔ ھﻲ ﻣﺗﺟﺎوز ﻧﺷﺎط ﻣﺛﺑطﺎت ﻋﺎﻣل اﻟﺗﺟﻠط اﻟﺛﺎﻣن * ﯾﺣﺗوي ﻛل 1 ﻣﻠﻠﻲ ﻋﻠﻰ 50 وﺣدة ﻣن ﻣﺗﺟﺎوز ﻧﺷﺎط ﻣﺛﺑطﺎت ﻋﺎﻣل اﻟﺗﺟﻠط اﻟﺛﺎﻣن * ﯾﺗوﻓر ﻓﺎﯾﺑﺎ 50 وﺣدة/ﻣل ﻓﻲ ﺛﻼﺛﺔ ﻋﺑوات ﻣﺧﺗﻠﻔﺔ: * ﺗﺣﺗوي اﻟﻌﺑوة ﻣن ﻓﺎﯾﺑﺎ )FEIBA( ﺑﺟرﻋﺔ 500 وﺣدة ﻋﻠﻰ 500 وﺣدة ﻣن ﻣﺗﺟﺎوز ﻧﺷﺎط ﻣﺛﺑطﺎت ﻋﺎﻣل اﻟﺗﺟﻠط &nbsp;اﻟﺛﺎﻣن ﻓﻲ 600-200 ﻣﺟم ﻣن ﺑروﺗﯾن اﻟﺑﻼزﻣﺎ اﻟﺑﺷري.&nbsp;<br />*ﺗﺣﺗوي اﻟﻌﺑوة ﻣن ﻓﺎﯾﺑﺎ )FEIBA( ﺑﺟرﻋﺔ 500 وﺣدة ﻋﻠﻰ 10000 وﺣدة ﻣن ﻣﺗﺟﺎوز ﻧﺷﺎط ﻣﺛﺑطﺎت ﻋﺎﻣل اﻟﺗﺟﻠط &nbsp;اﻟﺛﺎﻣن ف40001,20000 ﻣﺟم ﻣن ﺑروﺗﯾن اﻟﺑﻼزﻣﺎ اﻟﺑﺷري.&nbsp;<br />*ﺗﺣﺗوي اﻟﻌﺑوة ﻣن ﻓﺎﯾﺑﺎ )FEIBA( ﺑﺟرﻋﺔ 500 وﺣدة ﻋﻠﻰ 25000 وﺣدة ﻣن ﻣﺗﺟﺎوز ﻧﺷﺎط ﻣﺛﺑطﺎت ﻋﺎﻣل اﻟﺗﺟﻠط &nbsp;اﻟﺛﺎﻣن ف600-1,003,000 ﻣﺟم ﻣن ﺑروﺗﯾن اﻟﺑﻼزﻣﺎ اﻟﺑﺷري. - ﯾﺣﺗوي ﻓﺎﯾﺑﺎ )FEIBA( ﻛذﻟك ﻋﻠﻰ ﻛل ﻣن اﻟﻌﺎﻣل اﻟﺛﺎﻧﻲ واﻟﺗﺎﺳﻊ واﻟﻌﺎﺷر، وذﻟك ﺑﺷﻛل أﺳﺎﺳﻲ ﻓﻲ ﺷﻛل ﻏﯾر ﻣﻧﺷط ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ اﻟﻌﺎﻣل اﻟﺳﺎﺑﻊ اﻟﻣﻧﺷط. ﯾوﺟد ﻛل ﻣن ﻣﺳﺗﺿد ﺗﺟﻠط اﻟﻌﺎﻣل اﻟﺛﺎﻣن )F VIII C:Ag( وﻋواﻣل ﻧظﺎم &nbsp;ﻛﺎﻟﯾﻛراﯾن-ﻛﯾﻧﯾن ﻓﻘط ﺑﻛﻣﯾﺎت ﺿﺋﯾﻠﺔ، إن وﺟدوا. &nbsp; - اﻟﻣﻛوﻧﺎت اﻷﺧرى ھﻲ ﻛﻠورﯾد اﻟﺻودﯾوم وﺳﺗرات اﻟﺻودﯾوم اﻟﻣذﯾب &nbsp;ﻣﺎء ﻟﻠﺣﻘن &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;اﻟﺷﻛل اﻟﺻﯾدﻟﻲ: 1 &times; 500 وﺣدة 1 &times; 1000 وﺣدة 1 &times; 2500 وﺣدة &nbsp; &nbsp; ﻣﺣﺗوﯾﺎت اﻟﻌﺑوة: &nbsp;<br />- 1ﻗﻧﯾﻧﺔ ﺗﺿم ﻣﺳﺣوق ﻓﺎﯾﺑﺎ )FEIBA( ﺑﺟرﻋﺔ 500 وﺣدة / 1000 وﺣدة / 2500 وﺣدة ﻟﻌﻣل ﻣﺣﻠول ﻟﻠﺗﺳرﯾب &nbsp; &nbsp;- - 1 ﻗﻧﯾﻧﺔ ﺑﮭﺎ 10 ﻣﻠﻠﻲ/20 ﻣﻠﻠﻲ / 50 ﻣﻠﻠﻲ ﻣن اﻟﻣﺎء ﻟﻠﺣﻘن &nbsp;- &nbsp;ﻟﻺذاﺑﺔ BAXJECT II Hi-Flow ﺟﮭﺎز 1 - &nbsp; &nbsp;- &nbsp;ﻣﺣﻘﻧﺔ واﺣدة أﺣﺎدﯾﺔ اﻻﺳﺗﺧدام &nbsp; -إﺑرة واﺣدة أﺣﺎدﯾﺔ اﻻﺳﺗﺧدام &nbsp;- إﺑرة ﻓراﺷﯾﺔ واﺣدة ذات ﻣﺷﺑك&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>-----</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Baxter AG, Industriestrasse 67, A-1221 Vienna</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
ﺗﻣت اﻟﻣراﺟﻌﺔ اﻷﺧﯾرة ﻟﮭذه اﻟﻧﺷرة ﻓﻲ ﺳﺑﺗﻣﺑر 2019 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FEIBA 50 U/ml powder and solvent for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: Factor VIII Inhibitor Bypassing Activity

1 ml contains 50 U* factor VIII inhibitor bypassing activity. FEIBA 50 U/ml is available in three different presentations:
-	The presentation 500 U FEIBA contains 500 U factor VIII inhibitor bypassing activity in 200
– 600 mg human plasma protein,
-	The presentation 1000 U FEIBA contains 1000 U factor VIII inhibitor bypassing activity in 400 – 1,200 mg human plasma protein,
-	The presentation 2500 U FEIBA contains 2500 U factor VIII inhibitor bypassing activity in 1,000 – 3,000 mg human plasma protein.

FEIBA also contains the factors II, IX and X, mainly in non-activated form, as well as activated factor VII. Factor VIII coagulation antigen (F VIII C:Ag) is present at a concentration of up to
0.1 U./1 U. FEIBA. The factors of the kallikrein-kinin system are present in trace amounts only, if at all.

* 1 unit of FEIBA shortens the activated partial thromboplastin time (aPTT) of a factor VIII inhibitor plasma by 50% of the buffer value (blank value).

Excipients with known effect:
1.8 mmol sodium (40 mg) per vial with 500 U FEIBA.
3.6 mmol sodium (80 mg) per vial with 1000 U FEIBA.
8.9 mmol sodium (200 mg) per vial with 2500 U FEIBA. For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for infusion.

White, off-white or pale green powder. The pH value of the ready-to-use solution is between 6.8 and 7.6.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of bleeding in hemophilia A patients with inhibitors. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Treatment of bleeding in hemophilia B patients with inhibitors, if no other specific treatment is available (see section 5.1).<br />Treatment of bleeding in non-hemophiliacs with acquired inhibitors to factor VIII.<br />Prophylaxis of bleeding in hemophilia A patients with inhibitors who have experienced a significant bleed or are at high risk of significant bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment is to be initiated and monitored by a physician experienced in the treatment of coagulation disorders.</p><p>Posology<br />Dosage and duration of treatment depend on the severity of the haemostatic disorder, the localization and the extent of the bleeding, as well as the clinical condition of the patient.<br />Dosage and frequency of administration should always be guided by the clinical efficacy in each individual case.<br />As a general guideline, a dose of 50 &ndash;100 U FEIBA per kg body weight is recommended; a single dose of 100 U/kg body weight and a maximum daily dose of 200 U/kg body weight must not be exceeded unless the severity of bleeding warrants and justifies the use of higher doses.<br />See section 4.4.</p><p>Paediatric use (children)<br />The experience in children under 6 years of age is limited; the same dose regimen as in adults should be adapted to the child&rsquo;s clinical condition.</p><p>1)&nbsp;&nbsp; &nbsp;Spontaneous bleeding<br />Joint, muscle and soft tissue hemorrhage<br />A dose of 50 &ndash; 75 U/kg body weight at 12-hour intervals is recommended for minor to moderately severe bleeding. The treatment is to be continued until a clear improvement of the clinical symptoms, e.g. reduction of pain, decrease of swelling or increase of joint mobility, occurs.<br />For severe muscle and soft tissue bleeding, e.g. retroperitoneal hemorrhages, a dose of 100 U/kg body weight at 12-hour intervals is recommended. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Mucous membrane hemorrhage<br />A dose of 50 U/kg body weight every 6 hours under careful monitoring of the patient (visual control of bleeding, repeated determination of hematocrit) is recommended. If the bleeding does not stop, the dose may be increased to 100 U/kg body weight, however a daily dose of 200 U/kg body weight must not be exceeded.</p><p>Other severe hemorrhages &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; In severe hemorrhage, such as CNS bleeding, a dose of 100 U/kg body weight at 12-hour intervals is recommended. In individual cases, FEIBA may be administered at 6-hour intervals, until clear improvement of the clinical condition is achieved. (The maximum daily dose of 200 U/kg body weight must not be exceeded!)</p><p>2)&nbsp;&nbsp; &nbsp;Surgery<br />In surgical interventions, an initial dose of 100 U/kg body weight may be administered preoperatively, and a further dose of 50 &ndash; 100 U/kg body weight may be administered after 6 &ndash; 12 hours. As a postoperative maintenance dose, 50 &ndash; 100 U/kg body weight may be administered at 6 &ndash; 12-hour intervals; dosage, dosage intervals and duration of the peri- and postoperative therapy are guided by the surgical intervention, the patient&rsquo;s general condition and the clinical efficacy in each individual case. (The maximum daily dose of 200 U/kg body weight must not be exceeded!)</p><p>3)&nbsp;&nbsp; &nbsp;Prophylaxis in hemophilia A patients with inhibitors<br />Prophylaxis of bleeding in patients with a high inhibitor titer and frequent hemorrhages after failed immune tolerance induction (ITI) or when an ITI is not considered:<br />a dose of 70 &ndash; 100 U/kg body weight every other day is recommended. If necessary, the dose may be increased to 100 U/kg body weight per day or it may be decreased gradually.</p><p>Prophylaxis of bleeding in patients with a high inhibitor titer during an immune tolerance induction (ITI):<br />FEIBA may be administered concomitantly with factor VIII administration, in a dosage range of 50 &ndash; 100 U/kg body weight, twice per day, until the factor VIII inhibitor titer has decreased to &lt; 2 B.U.*<br />1 Bethesda Unit is defined as the amount of antibodies which inhibits 50% factor VIII activity in incubated plasma (2 h at 37&deg;C).</p><p>4)&nbsp;&nbsp; &nbsp;Use of FEIBA in special patient groups<br />See Section 5.1 for information in relation to hemophilia B patients with factor IX inhibitor.<br />In combination with factor VIII concentrate, FEIBA was also used for long term therapy to achieve complete and permanent elimination of the factor VIII inhibitor.</p><p>Monitoring<br />In case of inadequate response to treatment with the product, it is recommended that a platelet count be performed because a sufficient number of functionally intact platelets are considered to be necessary for the efficacy of the product.<br />Due to the complex mechanism of action, no direct monitoring of active ingredients is available. Coagulation tests such as the whole blood coagulation time (WBCT), the thromboelastogram (TEG, r-value) and the aPTT usually show only little reduction and do not necessarily correlate with the clinical efficacy. Therefore these tests have little significance in the monitoring of the therapy with FEIBA. See section 4.4.</p><p>Method of administration<br />Reconstitute the product as described in section 6.6 and slow infusion via the intravenous route. An infusion rate of 2 U/kg body weight per minute must not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

•	Hypersensitivity to the product or any of the components.
•	Disseminated Intravascular Coagulation (DIC).
•	Acute thrombosis or embolism (including myocardial infarction).

See section 4.4.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>WARNINGS<br />Hypersensitivity Reactions<br />FEIBA can precipitate allergic-type hypersensitivity reactions that have included, urticaria, angioedema, gastrointestinal manifestations, bronchospasm, and hypotension; these reactions can be severe and can be systemic (e.g., anaphylaxis with urticaria and angioedema, bronchospasm, and circulatory shock). Other infusion reactions, such as chills, pyrexia, and hypertension have also been reported.<br />Patients should be informed of the early signs of hypersensitivity reactions, for example erythema, skin rash, generalized urticaria, pruritus, breathing difficulties/dyspnoea, tightness of the chest, general indisposition, dizziness and drop in blood pressure up to allergic shock.<br />At the first sign or symptom of an infusion/hypersensitivity reaction, FEIBA administration should be stopped and medical care initiated as appropriate.<br />When considering re-exposure to FEIBA in patients with suspected hypersensitivity to the product or any of its components, the expected benefit and the risk of re-exposure must be carefully weighed, taking into account the known or suspected type of the patient&rsquo;s hypersensitivity (allergic or non-allergic), including potential remedial and/or preventative therapy or alternative therapeutic agents.</p><p>Thrombotic and Thromboembolic Events<br />Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, have occurred in the course of treatment with FEIBA.</p><p>Some of these events occurred with doses above 200 U/kg/day or in patients with other risk factors (including DIC, advanced atherosclerotic disease, crush injury or septicemia) for thromboembolic events. Concomitant treatment with recombinant Factor VIIa likely increases the risk of developing a thromboembolic event. The risk of thrombotic and thromboembolic events may be increased with high doses of FEIBA.<br />The possible presence of such risk factors should always be considered in patients with congenital and acquired hemophilia.</p><p>FEIBA should be used with particular caution and only if there are no therapeutic alternatives in patients with an increased risk of thromboembolic complications. These include, but are not limited to, patients with a history of coronary heart disease, liver disease, DIC, arterial or venous thrombosis, post-operative immobilization, elderly patients and neonates.<br />Thrombotic microangiopathy (TMA) has not been reported in FEIBA clinical studies. Cases of TMAs were reported in an emicizumab clinical trial where subjects received FEIBA as part of a treatment regimen for breakthrough bleeding (clinical discussion in the European Public Assessment Report (EPAR) of emicizumab; see also Oldenburg et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017:377:809-818).<br />The safety and efficacy of FEIBA for breakthrough bleeding in patients receiving emicizumab has not been established.<br />Therefore, benefit-risk evaluation of FEIBA to be administered to emicizumab exposed patients is required, and patients must be closely monitored by their physicians. (see also section 4.5.) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; If signs or symptoms of thrombotic and thromboembolic events are observed, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated. A single dose of 100 U/kg body weight and a daily dose of 200 U/kg body weight should not be exceeded unless the severity of bleeding warrants and justifies the use of higher doses.<br />When used to stop bleeding, the product should be given only for as long as absolutely necessary to achieve the therapeutic goal.</p><p>Therapy monitoring<br />Individual doses of 100 U/kg body weight and daily doses of 200 U/kg body weight must not be exceeded. Patients receiving 100 U/kg body weight or more must be monitored carefully, particularly for the development of DIC and/or acute coronary ischemia and for symptoms of other thrombotic or thromboembolic events. High doses of FEIBA should be administered only as long as strictly necessary &ndash; in order to stop a hemorrhage.<br />If clinically significant changes in blood pressure or pulse rate, respiratory distress, coughing or chest pain occur, the infusion is to be discontinued immediately and appropriate diagnostic and therapeutic measures are to be initiated. Significant laboratory parameters for DIC are a drop in fibrinogen, a drop of the thrombocyte count and/or the presence of fibrin/fibrinogen degradation products (FDP). Other parameters for DIC are a clearly prolonged thrombin time, prothrombin time or aPTT. In patients with inhibitor hemophilia or with acquired inhibitors to factors VIII, IX and/or XI, the aPTT is prolonged by the underlying disease.<br />Patients with inhibitor hemophilia or with acquired inhibitors to coagulation factors, who are treated with FEIBA, may have increased bleeding tendency as well as increased risk of thrombosis at the same time.</p><p>Laboratory tests and clinical efficacy<br />In vitro tests, such as aPTT, whole blood coagulation time (WBCT) and thromboelastograms (TEG) as proof of efficacy do not have to correlate with the clinical picture. Therefore, attempts to normalize these values by increasing the dose of FEIBA cannot be successful, and are even to be strongly rejected because of the possible risk of triggering a DIC through overdosing.</p><p>Significance of the thrombocyte count<br />If the response to treatment with FEIBA is inadequate, conducting a thrombocyte count is recommended since a sufficient number of functionally intact thrombocytes is necessary for the efficacy of FEIBA.</p><p>PRECAUTIONS<br />Thrombotic and Thromboembolic Complications<br />In the following situations, FEIBA is to be applied only if no reaction to treatment with suitable blood coagulation factor concentrates can be expected &ndash; e.g. in case of a high inhibitor titer and a life-threatening hemorrhage or risk of bleeding (e.g. post-traumatically or postoperatively):<br />-&nbsp;&nbsp; &nbsp;Disseminated intravascular coagulation (DIC): laboratory findings and/or clinical symptoms &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp;&nbsp; &nbsp;Liver damage: Due to the delayed clearance of activated coagulation factors, patients with impaired liver function are at increased risk of developing DIC.<br />-&nbsp;&nbsp; &nbsp;Coronary heart disease, acute thrombosis and/or embolism.</p><p>Patients who receive FEIBA should be monitored for the development of DIC, acute coronary ischemia, and signs and symptoms of other thrombotic or thromboembolic events. At the first signs or symptoms of thrombotic and thromboembolic events, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated.</p><p>Discordant Response to Bypassing Agents<br />Due to patient-specific factors the response to a bypassing agent can vary, and in a given bleeding situation patients experiencing insufficient response to one agent may respond to another agent. In case of insufficient response to one bypassing agent, use of another agent should be considered.</p><p>Anamnestic Responses<br />Administration of FEIBA to patients with inhibitors may result in an initial &ldquo;anamnestic&rdquo; rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time.<br />Clinical and published data suggest that the efficacy of FEIBA is not reduced.</p><p>Interference with Laboratory Tests<br />After administration of high doses of FEIBA, the transitory rise of passively transferred Hepatitis B surface antibodies may result in misleading interpretation of positive results in serological testing.<br />FEIBA contains blood group isohemagglutinins (anti-A and anti-B). Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, D, may interfere with some serological tests for red cell antibodies, such as antiglobulin test (Coombs test).</p><p>Pediatrics<br />Case reports and limited clinical trial data suggest that FEIBA can be used in children younger than 6 years of age. The same dose regimen as in adults should be adapted to the child&rsquo;s clinical condition.</p><p>Elderly<br />There are only limited clinical trial data with the use of FEIBA in elderly patients.</p><p>Prophylactic use in hemophilia B patients with inhibitors<br />Due to the rarity of the disease, only limited clinical data is available for the prophylaxis of bleeding in hemophilia B patients (literature case reports, n = 4, and clinical data in prophylaxis study 090701, n = 1).</p><p>Transmission of infectious agents<br />Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation / removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.<br />The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped virus HAV. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).</p><p>It is strongly recommended that every time that FEIBA is administered to the patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.<br />Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/ repeated receipt of human plasma-derived products including FEIBA.</p><p>Excipient related considerations<br />FEIBA 50 U/ml contains approximately 4 mg sodium (calculated) per ml; it is approx. 40 mg sodium for the presentation 500 U FEIBA, approx. 80 mg sodium for the presentation 1000 U FEIBA and approx. 200 mg sodium for the presentation 2500 U FEIBA. This is to be taken into consideration in patients on a low sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No adequate and well-controlled studies of the combined or sequential use of FEIBA NF and recombinant Factor VIIa, antifibrinolytics or emicizumab have been conducted. The possibility of thromboembolic events should be considered when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used during treatment with FEIBA. Therefore, antifibrinolytics should not be used for approximately 6 to 12 hours after the administration of FEIBA.<br />In cases of concomitant rFVIIa use a potential drug interaction cannot be excluded according to available in vitro data and clinical observations (potentially resulting in adverse events such as a thromboembolic event).<br />Clinical experience from an emicizumab clinical trial suggests that a potential drug interaction may exist with emicizumab when FEIBA was used as part of a treatment regimen for breakthrough bleeding which may result in thromboembolic events and thrombotic microangiopathy (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no adequate data from the use of FEIBA in pregnant or lactating women. Physicians should balance the potential risks and only prescribe FEIBA if clearly needed, taking into consideration that pregnancy and the postpartum period confer an increased risk of thromboembolic events, and several complications of pregnancy that are associated with an increased risk of DIC.<br />No animal reproduction studies have been conducted with FEIBA, and the effects of FEIBA on fertility have not been established in controlled clinical trials.<br />See section 4.4 for information on parvovirus B19 infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FEIBA has no, or negligible, influence on the ability to drive or to use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FEIBA can precipitate allergic-type hypersensitivity reactions that have included urticaria, angioedema, gastrointestinal manifestations, bronchospasm, and a drop in blood pressure; these reactions can be severe and can be systemic (e.g., anaphylaxis with urticaria and angioedema, bronchospasm, and circulatory shock). See also section 4.4 Hypersensitivity Reactions.</p><p>The adverse reactions presented in this section have been reported from post marketing surveillance as well as from 2 studies with FEIBA for the treatment of bleeding episodes in pediatric and adult patients with hemophilia A or B and inhibitors to factors VIII or IX. One study also enrolled acquired hemophilia patients with factor VIII inhibitors (2 of 49 patients). The adverse reactions from a third study comparing prophylaxis with on-demand treatment have been added.<br />&nbsp;<br />Frequency categories are defined according to the following convention: very common&nbsp;&nbsp; &nbsp;&ge; 1/10<br />common&nbsp;&nbsp; &nbsp;&ge; 1/100 to &lt;1/10 uncommon&nbsp;&nbsp; &nbsp;&ge; 1/1,000 to &lt;1/100 rare&nbsp;&nbsp; &nbsp;&ge; 1/10,000 to &lt;1/1,000<br />very rare&nbsp;&nbsp; &nbsp;&lt; 1/10,000<br />unknown&nbsp;&nbsp; &nbsp;cannot be estimated from the available data &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Class Reactions<br />Other symptoms of hypersensitivity reactions to plasma-derived products include lethargy and restlessness.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of FEIBA is important. It allows continued monitoring of the benefit/risk balance of FEIBA. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:</p><p>To report any side effect(s):<br />Kingdom of Saudi Arabia<br />-National Pharmacovigilance centre (NPC)<br />&bull;&nbsp;&nbsp; &nbsp;Fax: +966-11-205-7662<br />&bull;&nbsp;&nbsp; &nbsp;Call NPC at +966-11-2038222, Ext: 2317-2356-2340<br />&bull;&nbsp;&nbsp; &nbsp;Reporting hotline: 19999<br />&bull;&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa<br />&bull;&nbsp;&nbsp; &nbsp;Website: www.sfda.gov.sa/npc</p><p style="text-indent:50px"><br />&bull;&nbsp;&nbsp; &nbsp;Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The risk of thrombotic and thromboembolic events (including DIC, myocardial infarction, venous thrombosis, and pulmonary embolism) may be increased with high doses of FEIBA. Some of the reported thromboembolic events occurred with doses above 200 U/kg or with patients with other risk factors for thromboembolic events. If signs or symptoms of thrombotic and thromboembolic events are observed, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated. See section 4.4.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: blood coagulation factors, ATC code: B02BD03.</p><p>Although FEIBA was developed in the early seventies and its factor VIII inhibitor bypassing activity has been proven in vitro as well as in vivo, its mode of action is still the subject of scientific discussion. FEIBA, as found with activity assays, is composed of prothrombin complex zymogens which are both procoagulant (prothrombin FVII, FIX, FX) and anticoagulant (protein C) in relatively equal quantities to the arbitrary FEIBA potency unit but its procoagulant enzyme content is relatively low. FEIBA, thus, contains the proenzymes of the prothrombin complex factors, but only very small amounts of their activation products, with the contents of FVIIa being the highest. [Turecek PL and Schwarz HP. Chapter 4: Factor Eight Inhibitor Bypassing Activity, in Production of Plasma Proteins for Therapeutic Use, eds.<br />Joseph Bertolini, Neil Goss, John Curling, Wiley 2013, ISBN: 978-0-470-92431-0].</p><p>Current scientific works point to the role of specific components of the activated prothrombin complex, prothrombin (F II) and activated factor X (FXa) in the mode of action of FEIBA. [Turecek PL, Varadi K, Gritsch H, et al. Factor Xa and Prothrombin: Mechanism of Action of FEIBA. Vox Sang. 77: 72-79, 1999]<br />FEIBA controls bleeding by induction and facilitation of thrombin generation, a process for which the formation of the prothrombinase-complex is crucial. A number of biochemical in vitro and in vivo studies have shown that FXa and prothrombin play a critical role in the activity of FEIBA. The prothrombinase complex has been found to be a major target site for FEIBA. Apart from prothrombin and FXa, FEIBA contains other proteins of the prothrombin complex, which could also facilitate haemostasis in haemophilia patients with inhibitors.</p><p><br />Treatment of hemophilia B patients with inhibitors<br />The experience in hemophilia B patients with factor IX inhibitors is limited due to the rarity of the disease. Five hemophilia B patients with inhibitors were treated with FEIBA during clinical trials either on-demand, prophylactically or for surgical interventions:</p><p>In a prospective open-label, randomized, parallel clinical study in hemophilia A or B patients with persistent high-titer inhibitors (090701, PROOF), 36 patients were randomized to either 12 months &plusmn; 14 days of prophylactic or on-demand therapy. The 17 patients in the prophylaxis arm received 85 &plusmn; 15 U/kg FEIBA administered every other day and the 19 patients in the on- demand arm were treated individually determined by the physician. Two hemophilia B patients with inhibitors were treated in the on-demand arm and one hemophilia B patient was treated in the prophylactic arm.<br />The median ABR (annualized bleeding rate) for all types of bleeding episodes in patients in the prophylaxis arm (median ABR = 7.9) was less than that of patients in the on-demand arm (median ABR = 28.7), which amounts to a 72.5% reduction in median ABRs between treatment arms.</p><p>In another completed prospective non-interventional surveillance study of the perioperative use of FEIBA (PASS-INT-003, SURF) a total of 34 surgical procedures were performed in 23 patients. The majority of patients (18) were congenital hemophilia A patients with inhibitors, two were hemophilia B patients with inhibitors and three were patients with acquired hemophilia A with inhibitors. The duration of FEIBA exposure ranged from 1 to 28 days, with a mean of 9 days and a median of 8 days. The mean cumulative dose was 88,347 U and the median dose was 59,000 U. For hemophilia B patients with inhibitors, the longest exposure to FEIBA was 21 days and the maximum dose applied was 7324 U.<br />In addition 36 case reports are available when FEIBA was used for treatment and prevention of bleeding episodes in hemophilia B patients with factor IX inhibitor (24 hemophilia B patients with inhibitors were treated on-demand, four hemophilia B patients with inhibitors were treated prophylactically and eight hemophilia B patients with inhibitors were treated for surgical procedures).</p><p>There are also isolated reports on the use of FEIBA in the treatment of patients with acquired inhibitors to factors X, XI and XIII.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As the mode of action of FEIBA is still being discussed, it is not possible to make a conclusive statement about the pharmacokinetic properties.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on acute toxicity studies in factor VIII knockout mice and in normal mice, and in rats, with doses higher than the maximum daily dose in humans (&gt; 200 U/kg body weight), it can be concluded that the side effects in connection with FEIBA are mainly the result of hypercoagulation due to the pharmacological properties.</p><p>Toxicity studies with repeated administration in animal experiments are practically unfeasible as interference occurs through the development of antibodies to heterologous proteins.</p><p>Since human blood coagulation factors are not seen as carcinogenic or mutagenic, experimental animal studies, especially in heterologous species, were not considered necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder:&nbsp;&nbsp; &nbsp;Sodium chloride Sodium citrate</p><p>Solvent:&nbsp;&nbsp; &nbsp;Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except the solvent mentioned in section 6.6.<br />As in all blood coagulation preparations, the efficacy and tolerance of the medicinal product may be impaired by being mixed with other medicinal products. It is advisable to rinse a common venous access with a suitable solution, e.g. with isotonic saline solution, before and after the administration of FEIBA.<br />Coagulation factors derived from human plasma may be adsorbed by the inner surfaces of certain types of injection/infusion devices. If this were to occur, it could result in failure of therapy. Therefore, only approved plastic infusion devices may be used with FEIBA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Two years.

Chemical and physical in-use stability has been demonstrated for 3 hours at room temperature (up to 25°C). From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination (controlled and validated aseptic conditions), the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Reconstituted product must not be refrigerated.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Do not freeze.<br />Store in the original package in order to protect from light. For storage conditions of the reconstituted medicinal product &ndash; see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder is supplied in a vial made of surface treated, colorless glass (hydrolytic type I for 500 U, and 2500 U; hydrolytic type II for 1000 U). The solvent is supplied in a vial made of surface treated, colorless glass (hydrolytic type I for 10 ml, 20 ml and 50 ml. The vials are closed by a stopper made of butyl rubber.<br />FEIBA 50 U/ml is available in the following presentations: 1 x 500 U, 1 x 1000 U and 1 x 2500 U &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Presentation 500 U / 1000 U contains either</p><p>-&nbsp;&nbsp; &nbsp;1 vial with 500 U / 1000 U FEIBA powder for solution for infusion<br />-&nbsp;&nbsp; &nbsp;1 vial with 10 ml / 20 ml Water for Injections<br />-&nbsp;&nbsp; &nbsp;1 disposable syringe<br />-&nbsp;&nbsp; &nbsp;1 disposable needle<br />-&nbsp;&nbsp; &nbsp;1 butterfly needle with clamp<br />-&nbsp;&nbsp; &nbsp;1 filter needle<br />-&nbsp;&nbsp; &nbsp;1 transfer needle<br />-&nbsp;&nbsp; &nbsp;1 aeration needle<br />or<br />-&nbsp;&nbsp; &nbsp;1 vial with 500 U / 1000 U FEIBA powder for solution for infusion<br />-&nbsp;&nbsp; &nbsp;1 vial with 10 ml / 20 ml Water for Injections<br />-&nbsp;&nbsp; &nbsp;1 BAXJECT II Hi-Flow<br />-&nbsp;&nbsp; &nbsp;1 disposable syringe<br />-&nbsp;&nbsp; &nbsp;1 disposable needle<br />-&nbsp;&nbsp; &nbsp;1 butterfly needle with clamp</p><p>Presentation 2500 U contains</p><p>1 vial with 2500 U FEIBA powder for solution for infusion 1 vial with 50 ml Water for Injections<br />1 BAXJECT II Hi-Flow<br />1 disposable syringe<br />1 disposable needle<br />1 butterfly needle with clamp</p><p>Not all presentations or package variants may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FEIBA is to be reconstituted immediately prior to administration. The solution should be used immediately (as the preparation does not contain preservatives).</p><p>Swirl gently until all material is dissolved. Ensure that FEIBA is completely dissolved; otherwise, less FEIBA Units will pass through the device filter.</p><p>After reconstitution, the solution should be inspected for particulate matter and discoloration prior to administration. Do not use solutions which are cloudy or have deposits.</p><p>Open containers must not be re-used.</p><p>Do not use the product if its sterile barrier has been breached, its package damaged or if it shows signs of deterioration. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Use only the included Water for Injections and the included device set for reconstitution. If devices other than those enclosed are used, ensure the use of an adequate filter with a pore size of at least 149 &micro;m.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Reconstitution of the powder for preparing a solution for infusion with needles:<br />1.&nbsp;&nbsp; &nbsp;Warm the unopened solvent vial (Water for Injections) to room temperature or max. +37&deg;C if necessary.</p><p>2.&nbsp;&nbsp; &nbsp;Remove the protective caps from the powder vial and solvent vial (Fig. A) and disinfect the rubber stoppers of both vials.<br />3.&nbsp;&nbsp; &nbsp;Open the protective cap from one end of the enclosed transfer needle by twisting, remove it and insert the needle through the rubber stopper of the solvent vial (Fig. B and C).<br />4.&nbsp;&nbsp; &nbsp;Remove the protective cap from the other end of the transfer needle taking care not to touch the exposed end !<br />5.&nbsp;&nbsp; &nbsp;Invert the solvent vial and insert the free end of the transfer needle through the rubber stopper of the powder vial (Fig. D). The solvent will be drawn into the powder vial by vacuum.<br />6.&nbsp;&nbsp; &nbsp;Disconnect the two vials by removing the transfer needle from the powder vial (Fig. E). Gently swirl the powder vial to accelerate dissolution.<br />7.&nbsp;&nbsp; &nbsp;Upon complete reconstitution of the powder, insert the enclosed aeration needle (Fig. F) and any foam will collapse. Remove the aeration needle.</p><p>Infusion:<br />1.&nbsp;&nbsp; &nbsp;Open one end of the protective cap from the enclosed filter needle by twisting, remove it and fit the needle on to the sterile disposable syringe. Draw the solution into the syringe (Fig. G).<br />2.&nbsp;&nbsp; &nbsp;Disconnect the filter needle from the syringe and slowly administer the solution intravenously with the enclosed infusion set (or the enclosed disposable needle). &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Reconstitution of the powder for preparing a solution for infusion with the BaxJect II Hi- Flow:<br />1.&nbsp;&nbsp; &nbsp;Warm the unopened solvent vial (Water for Injections) to room temperature (15&deg;C to 25&deg;C), for example by using a water bath for several minutes (max. 37&deg;C) if necessary.</p><p>2.&nbsp;&nbsp; &nbsp;Remove the protective caps from the powder vial and solvent vial and disinfect the rubber stoppers of both vials. Place the vials on an even surface.<br />3.&nbsp;&nbsp; &nbsp;Open the packaging of the BAXJECT II Hi-Flow by pulling off the protective foil without touching the contents of the package (Fig. a). Do not remove the transfer system from the package at this point.<br />4.&nbsp;&nbsp; &nbsp;Turn the package around and press the transparent plastic pin through the rubber stopper of the solvent vial (Fig. b). Now remove the packaging from the BAXJECT II Hi-Flow (Fig. c). Do not remove the blue protective cap from the BAXJECT II Hi-Flow.<br />5.&nbsp;&nbsp; &nbsp;Now turn the system, consisting of the BAXJECT II Hi-Flow and the solvent vial, in such a way that the solvent vial is on top. Press the purple pin of the BAXJECT II Hi-Flow through the FEIBA vial. The solvent is drawn into the FEIBA vial by vacuum (Fig. d).<br />6.&nbsp;&nbsp; &nbsp;Swirl, but do not shake the entire system gently until the powder is dissolved. Make sure that the FEIBA has been dissolved completely, as active material may otherwise be retained by the filter in the system. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Infusion<br />1)&nbsp;&nbsp; &nbsp;Remove the blue protective cap from the BAXJECT II Hi-Flow. Tightly connect the syringe to the BAXJECT II Hi-Flow. DO NOT DRAW AIR INTO THE SYRINGE. (Fig. e). In order to ensure tight connection between syringe and BAXJECT II Hi- Flow, the use of a luer lock syringe is highly recommended (turn syringe in clockwise direction until stop position when mounting).<br />2)&nbsp;&nbsp; &nbsp;Invert the system so that the dissolved product is on top. Draw the dissolved product into the syringe by pulling the plunger back SLOWLY and ensure that the tight connection between BAXJECT II Hi-Flow and the syringe is maintained throughout the whole pulling process (Fig. f).<br />3)&nbsp;&nbsp; &nbsp;Disconnect the syringe.<br />4)&nbsp;&nbsp; &nbsp;If foaming of the product in the syringe occurs, wait until the foam is collapsed. Slowly administer the solution intravenously with the enclosed infusion set (or disposable needle).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxter AG, Vienna, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01-03-2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>